## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-Q

(Ma	rk One)		
X	QUARTERLY REPORT PURSUANT TO SEC	CTION 13 OR 15(d) OF THE SECURIT	TIES EXCHANGE ACT OF 1934
	1	For the quarterly period ended March 31, 2	2025
		or	
	TRANSITION REPORT PURSUANT TO SEC	CTION 13 OR 15(d) OF THE SECURIT	TIES EXCHANGE ACT OF 1934
	For the trans	sition period fromto	·
		Commission File Number: 001-38608	
	(Ex	Datavault AI Inc. xact name of registrant as specified in its cl	harter)
	Delaware		30-1135279
	(State or other jurisdiction of incorporation or o	organization)	(I.R.S. Employer Identification No.)
	(A	15268 NW Greenbrier Pkwy Beaverton, OR 97006 ddress of principal executive offices) (Zip	Code)
	(Re	(408) 627-4716 gistrant's telephone number, including area	a code)
		N/A	
~		mer address and former fiscal year, if char	nged since last report)
Secu	urities registered pursuant to Section 12(b) of the A	ct:	
	Title of each class  Common Stock, par value \$0.0001 per share	Trading symbol(s) DVLT	Name of each exchange on which registered The Nasdaq Capital Market
duri	cate by check mark whether the registrant (1) has	filed all reports required to be filed by Se	ection 13 or 15(d) of the Securities Exchange Act of 1934 file such reports), and (2) has been subject to such filing
Reg			ata File required to be submitted pursuant to Rule 405 of eriod that the registrant was required to submit such files).
eme			non-accelerated filer, a smaller reporting company, or an ," "smaller reporting company," and "emerging growth
	ge accelerated filer □ -accelerated filer ⊠		Accelerated filer □ Smaller reporting company ⊠ Emerging growth company □
	n emerging growth company, indicate by check-mag evised financial accounting standards provided purs		he extended transition period for complying with any new . $\Box$
Indi	cate by check mark whether the registrant is a shell	company (as defined in Rule 12b-2 of the	Exchange Act). Yes   No   No
	The number of shares of the registrant's common s	stock outstanding as of May 14, 2025 is 66	,024,190.
_			

## **DATAVAULT AI INC.** (formerly WiSA Technologies, Inc.) and Subsidiaries **QUARTERLY REPORT ON FORM 10-Q**For the quarter ended March 31, 2025

	Number
PART I: FINANCIAL INFORMATION	
Item 1. Financial Statements (unaudited)	
Condensed Consolidated Balance Sheets	3
Condensed Consolidated Statements of Operations	4
Condensed Consolidated Statements of Stockholders' Equity (Deficit)	5
Condensed Consolidated Statements of Cash Flows	6
Notes to Condensed Consolidated Financial Statements	7
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	38
Item 3. Quantitative and Qualitative Disclosures About Market Risk	40
Item 4. Controls and Procedures	41
PART II. OTHER INFORMATION	
Item 1. Legal Proceedings	42
Item 1A, Risk Factors	42
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	42
Item 3. Defaults Upon Senior Securities	42
Item 4. Mine Safety Disclosures	42
Item 5. Other Information	42
Item 6. Exhibits	43
SIGNATURES	44

### PART I: FINANCIAL INFORMATION

### **Item 1. Financial Statements**

### DATAVAULT AI INC. CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

	Ma	arch 31, 2025	Dec	ember 31, 2024
	(	unaudited)		(1)
Assets				
Current Assets:				
Cash and cash equivalents	\$	171	\$	3,330
Accounts receivable		280		349
Inventories		1,342		1,618
Prepaid expenses and other current assets		900		1,142
Total current assets		2,693		6,439
Property and equipment, net		98		58
Intangible assets		90,383		92,575
Deposit for business combination		2,000		1,000
Other assets		499		553
Total assets	\$	95,673	\$	100,625
Liabilities, Convertible Redeemable Preferred Stock and Stockholders' Deficit				
Current Liabilities:				
Accounts payable	\$	2,807	\$	2,779
Accrued liabilities		1,364		1,334
Total current liabilities		4,171		4,113
Convertible note payable, net, related party		9,283		9,569
Warrant liabilities		10		664
Other liabilities		523		553
Total liabilities		13,987		14,899
Commitments and contingencies (Note 8)				
Series B Convertible Redeemable Preferred Stock, par value \$0.0001; 375,000 shares authorized; 0 and 0				
shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively		_		_
, , , , ,				
Stockholders' Deficit:				
Common stock, par value \$0.0001; 300,000,000 shares authorized; 66,024,190 and 52,034,060 shares				
issued and outstanding as of March 31, 2025 and December 31, 2024, respectively		6		5
Additional paid-in capital		389,694		384,172
Accumulated deficit		(308,014)		(298,451)
Total stockholders' equity / (deficit)		81,686		85,726
Total liabilities, convertible preferred stock and stockholders' equity/(deficit)	\$	95,673	\$	100,625
	<u> </u>	,	<u> </u>	,

<sup>(1)</sup> The condensed consolidated balance sheet as of December 31, 2024 was derived from the audited consolidated balance sheet as of that date.

Note: Share and per share amounts have been retroactively adjusted to reflect the impact of a 1-for-150 reverse stock split effected in April 2024, as discussed in Note 1.

The accompanying notes are an integral part of these condensed consolidated financial statements

### DATAVAULT AI INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

For the three months ended March 31, 2025 and 2024 (in thousands, except share and per share data) (unaudited)

	Three Months Ended March 31,			
		2025		2024
Revenue, net	\$	629	\$	255
Cost of revenue		560		338
Gross profit (deficit)		69		(83)
Operating Expenses:				
Research and development		2,361		1,715
Sales and marketing		1,495		929
General and administrative		5,644		1,431
Total operating expenses		9,500		4,075
Loss from operations		(9,431)		(4,158)
Interest expense, net		(120)		(1,265)
Change in fair value of warrant liabilities		17		8,129
Other expense, net		(29)		1
Income (loss) before provision for income taxes		(9,563)		2,707
Provision for income taxes		_		_
Net income (loss)		(9,563)		2,707
Deemed dividend on conversion of Series B preferred for common stock and repurchase of Series B preferred				
stock		_		(5,842)
Net loss attributable to common stockholders	\$	(9,563)	\$	(3,135)
Net loss per common share - basic and diluted	\$	(0.18)	\$	(5.35)
Weighted average number of common shares used in computing net loss per common share		53,681,828		585,500

Note: Share and per share amounts have been retroactively adjusted to reflect the impact of a 1-for-150 reverse stock split effected in April 2024, as discussed in Note 1.

The accompanying notes are an integral part of these condensed consolidated financial statements.

# DATAVAULT AI INC. CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) For the three months ended March 31, 2025 and 2024 (in thousands, except share and per share data)

(unaudited)

		Preferred Stock	Common		Additional	Accumulated	Total Stockholders'
	Shares	Amount	Shares	Amount	Paid-in Capital	Deficit	Equity (Deficit)
Balance as of December 31, 2024		<u>s</u> —	52,034,060	\$ 5	\$ 384,172	\$ (298,451)	\$ 85,726
Stock-based compensation	_	_	5,986,893	_	648	_	648
Issuance of common stock in connection with the February Offering	_	_	4,757,126	1	4,859	_	4,860
Issuance of common stock in connection with alternative cashless warrant exercise	_	_	3,246,111	_	_	_	_
Conversion of liability warrants to equity warrants	_	_	· · · · · ·	_	15	_	15
Net loss	_	_	_	_	_	(9,563)	(9,563)
Balance as of March 31, 2025		s <u> </u>	66,024,190	\$ 6	\$ 389,694	\$ (308,014)	\$ 81,686

	Convertible Shares	Prefer	red Stock Amount	Common	Shares Amount	<u>_</u>	Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Equity (Deficit)
Balance as of December 31, 2023	38,335	\$	247	222,380	\$	Ī	\$ 241,884	\$ (247,042)	\$ (5,157)
Stock-based compensation	_		_	4	_	-	380	_	380
Cumulative effect of ASU 2020-06 adoption	_		116	_	_	-	(116)	_	(116)
Issuance of Series B preferred stock in connection with warrant exercise, net of discounts	29,322		386	_	_	-	-	_	
Issuance of common stock in connection with conversion of Series B preferred stock	(5,000)		(325)	8,038	_	-	325	_	325
Deemed dividend on conversion of Series B preferred for common stock and repurchase of Series B preferred stock	_		5,842	_	_	_	(5,842)	_	(5,842)
Repurchase of Series B preferred stock and Series B preferred stock warrants	(62,657)		(6,266)	_	_	-	824	_	824
Issuance of common stock, pre-funded units and warrants, net of offering costs	` ' _ '		`	1,442,518	_	-	4,210	_	4,210
Issuance of common stock in connection with reverse split rounding-up for fractional shares	_		_	84,255	_	-	_	_	_
Net income						_		2,707	2,707
Balance as of March 31, 2024				1,757,195	\$		\$ 241,665	\$ (244,335)	\$ (2,669)

Note: Share and per share amounts have been retroactively adjusted to reflect the impact of a 1-for-150 reverse stock split effected in April 2024, as discussed in Note 1.

The accompanying notes are an integral part of these condensed consolidated financial statements.

### DATAVAULT AI INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the three months ended March 31, 2025 and 2024 (in thousands) (unaudited)

Age file file file file file file file fil		Three Months l	Three Months Ended March 31,		
Net innome (loss)         \$ (9,56)         \$ 2,707           Aljustments to reconcile net lost to reconcile n		2025	2024		
Aginemis to reconcile nel loss to et cash used in operating activities					
Shock-based compensation         648         380           Depreciation and amoritazion         2,321         30           Depreciation and amoritazion         120         1,360           Depreciation and amoritazion         120         1,360           Changosi ne operating assets and liabilities         66         4           Changosi ne operating assets and other current assets         69         4           Il report of the properties of		\$ (9,563)	\$ 2,707		
Deprecision and amortization         2,321         20           Amortization of debt discounts         120         1,20           Change in fair value of warrant liabilities         (17)         (8,120)           Changes in equivaling assets and liabilities         26         188           Inventories         276         188           Prepaid expenses and other current assets         35         35           Other assets         43         34           Accounts payable         (20)         (20)           Other liabilities         (30)         (33)           Net can be din operating activities         (30)         (35)           Purposite of property and equipment         (100)         (35)           As flows from investing activities         (100)         (100)           Purchases of property and equipment         (100)         (100)           As flows from investing activities         494         —6           Cash flows from framening activities         494         —7           Propects from issuance of common stock, and of issuance costs         4,94         —7           Proceeds from issuance of short-term loan, and of issuance costs         4,94         —7           Proceeds from issuance of common stock and activation and activation and activation and		440	200		
Administration of beth discounts					
Changes in portang assets and labilities:         69         4           Accounts receivable         99         4           Inventories         276         158           Pepade expenses and other current assets         261         23           Accounts payable         30         (229)           Account labilities         30         (229)           Other labilities         (30)         (35)           Net cash used in operating activities         (1000)         7           Process for business combination         (1,000)         7           Process for business combination         (1,000)         60           Net cash used in investing activities         25         6           Cash flows from financing activities         4945         -           Cash flows from financing activities         4945         -           Proceeds from susance of short-term loan, net of issuance costs         4945         -           Proceeds from susance of short-term loan, net of issuance costs         -         15,57					
Case					
Accounts receivable         69         4           Inventories         276         158           Prepaid expense and other current assets         359         35           Other assets         291         223           Accounted liabilities         30         223           Other liabilities         30         230           Other liabilities         30         230           Other liabilities         (6024)         3,540           Cash flows from investing activities		(17)	(8,129)		
Prepaid expenses and other current assets	Changes in operating assets and habilities:	60	4		
Prepaid expenses and other current assets         54         34           Other assets         64         34           Accounts payable         (30)         223           Other liabilities         (30)         (33)         (229)           Other liabilities         (30)         (33)         (35)           Net cash used in operating activities					
Offer assers         54         34           Accounts payable         (291)         233           Account diabilities         30         (279)           Other Inabilities         30         (330)           Net each used in operating activities         """"         """"           Cash flows from investing activities         """         """           Purchases of properly and equipment         (52)         (60)           Net easily activities         """         """           Proceeds from insuance activities         """         """           Proceeds from insuance activities         """         """           Proceeds from insuance costs         """         """         600           Proceeds from insuance cost short-term loan, net of issuance costs         """         """         115,17           Proceeds from issuance of short-term loan issuance costs         """         """         140           Repurchase of Series B preferred stock and warrants         """         """         140           Repurchase of Series B preferred stock and warrants         """         """         160           Repurchase of Series B preferred stock and warrants         """         """         160           Repurchase of Ceries Bor Livities         """					
Accounts payable         (291)         223           Accounts labilities         30         (229)           Other liabilities         (30)         (3)           Net cast on operating activities         Test of thouse from investing activities         Test of thouse from investing activities           Purchases of property and equipment         (1000)         —           Net cash used in investing activities         Test of (1000)         —           Purchases of property and equipment         (1000)         —           Chest flows from finacing activities         Test of (1000)         —           Proceeds from issuance of common stock, and of issuance costs         —         —         —           Proceeds from issuance of short-term loan, and of issuance costs         —         —         —         —           Proceeds from issuance of short-term loan, and of issuance costs         —					
Accraed labilities					
Other liabilities         (3)         (4)         (5)         (6)					
Net cash used in operating activities         (6.024)         (3.540)           Cash flows from investing activities         (1,000)         —           Purchases of property and equipment         (52)         (6)           Net cash used in investing activities         (1,002)         (6)           Cash flows from financing activities         —         —           Proceeds from issuance of common stock, net of issuance costs         —         —         600           Proceeds from issuance of common stock and prefunded warrants, net of issuance costs         —         —         600           Proceeds from issuance of common stock warrants         —         —         600           Proceeds from issuance of common stock warrants         —         —         600           Proceeds from issuance of common stock warrants         —         —         600           Proceeds from issuance of common stock warrants         —         —         600           Repurchase of Series By prefered stock and warrants         —         —         620           Repurchase of Series By prefered stock and warrants         —         —         6670           Repayment of convertible note principal and accrued interest         —         6670         —           Repayment of short-term loan         —         6671					
Cash flows from investing activities:					
Deposits for business combination         (1,000)         ————————————————————————————————————	Net cash used in operating activities	(0,024)	(3,340)		
Purchases of property and equipment					
Net cash used in investing activities         (1,052)         (6)           Cash flows from financing activities:         —         Cash flows from financing activities:         —         Cash flows from issuance of common stock, net of issuance costs         —         600         —         600         —         600         —         600         —         600         —         11,517         —         714         Active Cash from issuance of common stock and prefunded warrants, net of issuance costs         —         600         —         714         Repurchase of common stock warrants         (622)         —         714         Repurchase of common stock warrants         —         76,266         36,20         —         714         Repurchase of Series B preferred stock and warrants         —         76,266         36,20         —         76,266         3,917         5,888         76,266         Repayment of short-term loan         —         76,670         3,917         5,888         3,917         5,888         3,917         5,888         3,918         2,525         2,763         2,525         2,763         2,763         2,763         2,763         2,763         2,763         2,763         2,763         2,763         2,763         2,763         2,763         2,763         2,763         2,763         2,763					
Cash flows from financing activities					
Proceeds from issuance of common stock, net of issuance costs         4,945         −         600           Proceeds from issuance of common stock and prefunded warrants, net of issuance costs         −         11,517           Proceeds from issuance of common stock warrants         −         714           Repurchase of Common stock warrants         −         (6,265)           Repurchase of Series B preferred stock and warrants         −         (6,266)           Repayment of convertible not principal and accrued interest         −         (6,267)           Repayment of short-term loan         −         (6,677)           Net decrease in cash and cash equivalents         3,917         5,898           Net decrease in cash and cash equivalents as of beginning of period         3,330         411           Cash and cash equivalents as of equivalents as of end of period         3,330         411           Cash and cash equivalents as of equivalents as of end of period         \$ 2,72           Supplemental disclosure of cash flow information:         \$ 171         \$ 2,72           Cash paid for interest         \$ 62         \$ 2,72           Nonesst Investing and Financing Activities:         \$ 117         \$ −           Capitalized acquistion cost         \$ 117         \$ −           Issuance of warrant liability in connection with financing	Net cash used in investing activities	(1,052)	(6)		
Proceeds from issuance of common stock, net of issuance costs         4,945         −         600           Proceeds from issuance of common stock and prefunded warrants, net of issuance costs         −         11,517           Proceeds from issuance of common stock warrants         −         714           Repurchase of common stock warrants         −         (622)         −           Repurchase of Series B preferred stock and warrants         −         (626)         −           Repayment of convertible not principal and accrued interest         (406)         −         6670           Repayment of short-term loan         −         (667)         5,866           Net decrease in cash and cash equivalents         (3,159)         2,352           Cash and cash equivalents as of beginning of period         3,330         411           Cash and cash equivalents as of equivalents as of end of period         \$ 171         \$ 2,763           Supplemental disclosure of cash flow information:         \$ 2         2.72           Cash paid for interest         \$ 62         \$ 2.72           Nonesst Investing and Financing Activities:         \$ 117         \$ −           Capitalized acquistion costs         \$ 117         \$ −           Issuance of warrant liability in connection with financing         \$ 5.71         \$ 8,701      <	Cash flows from financing activities:				
Proceeds from issuance of short-term loan, net of issuance costs         —         600           Proceeds from issuance of common stock and prefunded warrants, net of issuance costs         —         11,517           Proceeds from exercise of warrants         —         714           Repurchase of Common stock warrants         (622)         —           Repurchase of Series B preferred stock and warrants         —         (6,266)           Repayment of convertible note principal and accrued interest         (406)         —           Repayment of short-term floan         —         (667)           Net decrease in cash and cash equivalents         (3,159)         2,352           Cash and cash equivalents as of beginning of period         3,330         411           Cash and cash equivalents as of not of period         \$         17         2,763           Supplemental disclosure of cash flow information:		4 945	_		
Proceeds from issuance of common stock and prefunded warrants, net of issuance costs         —         11,517           Proceeds from exercise of warrants         —         714           Repurchase of common stock warrants         —         714           Repurchase of Series B preferred stock and warrants         (626)         —           Repayment of convertible note principal and accrued interest         (406)         —           Repayment of short-term loan         —         (627)         —           Net decrease in cash and cash equivalents         3,917         5,898           Net decrease in cash and cash equivalents as of beginning of period         3,330         411           Cash and cash equivalents as of equivalents as of end of period         5 171         5 2,732           Supplemental disclosure of eash flow information:         S         5         2.72           Noncash Investing and Financing Activities:         S         5         2.72           Noncash Investing and Financing Activities:         S         5         8.70           Issuance of warrant liability in connection with financing         S         3.870         5         8.70           Deemed dividend on conversion of Series B preferred stock and repurchase of Series B preferred stock         S         8.86         9.714           Unpaid financin		-	600		
Proceeds from exercise of warrants		_			
Repurchase of Common stock warrants         (622)         —           Repurchase of Series B preferred stock and warrants         —         (6,266)           Repayment of convertible note principal and accrued interest         4(406)         —           Repayment of short-term loan         —         (667)           Net ash provided by financing activities         3,917         5,898           Net decrease in cash and cash equivalents         (3,159)         2,352           Cash and cash equivalents as of beginning of period         3,330         411           Cash and cash equivalents as of end of period         \$ 171         \$ 2,763           Supplemental disclosure of cash flow information:           Cash paid for interest         \$ 62         \$ 272           Noncash Investing and Financing Activities:           Cash paid acquistion costs         \$ 117         \$ 8,701           Issuance of warrant liability in connection with financing         \$ 8,701         \$ 8,701           Unpaid financings issuance costs         \$ 86         \$ 7,14           Unpaid deferred offering costs         \$ 15         \$ 6,842           Unpaid deferred offering costs         \$ 15         \$ 6,842           Unpaid deferred offering costs         \$ 15         \$ 7,14           Unpaid deferr	Proceeds from exercise of warrants	_			
Repurchase of Series B preferred stock and warrants         (6,666)           Repayment of convertible note principal and accrued interest         (406)         —           Repayment of short-tern loan         —         (667)           Net cash provided by financing activities         3,917         5,898           Net decrease in cash and cash equivalents         (3,159)         2,352           Cash and cash equivalents as of beginning of period         3,330         411           Cash and cash equivalents as of end of period         5         171         2,763           Supplemental disclosure of cash flow information:         S         62         2,722           Noncash Investing and Financing Activities:         S         62         2,722           Noncash Investing and Financing Activities:         S         117         5           Capitalized acquisition costs         S         117         5           Issuance of warrant liability in connection with financing         S         5         6         5,742           Unpaid financings issuance costs         S         117         S         —           Unpaid deferred offering costs         S         117         S         —           Reclass liability warrant to equity         S         15         — <tr< td=""><td>Repurchase of common stock warrants</td><td>(622)</td><td></td></tr<>	Repurchase of common stock warrants	(622)			
Repayment of short-term loan         — (667)           Net cash provided by financing activities         3,917         5,898           Net decrease in cash and cash equivalents         (3,159)         2,352           Cash and cash equivalents as of beginning of period         3,330         411           Cash and cash equivalents as of end of period         \$ 171         \$ 2,763           Supplemental disclosure of cash flow information:           Cash paid for interest         \$ 62         \$ 272           Noncash Investing and Financing Activities:           Capitalized acquistion costs         \$ 117         \$ —           Issuance of warrant liability in connection with financing         \$ 5         17         \$ 5           Unpaid financings issuance costs         \$ 5         17         \$ 7         \$ 5,870           Unpaid deferred offering costs         \$ 5         17         \$ —         \$ 6,5842         \$ 7,14           Unpaid deferred offering costs         \$ 15         \$ —         \$ 6,5842         \$ 7,14           Unpaid deferred offering costs         \$ 117         \$ —         \$ 6,5842         \$ 7,14           Unpaid deferred offering costs         \$ 15         \$ —         \$ 6,5842         \$ 7,14           Unpaid deferred offering costs         <		`_'	(6,266)		
Repayment of short-term loan         — (667)           Net cash provided by financing activities         3,917         5,898           Net decrease in cash and cash equivalents         (3,159)         2,352           Cash and cash equivalents as of beginning of period         3,330         411           Cash and cash equivalents as of end of period         \$ 171         \$ 2,763           Supplemental disclosure of cash flow information:           Cash paid for interest         \$ 62         \$ 272           Noncash Investing and Financing Activities:           Capitalized acquistion costs         \$ 117         \$ —           Issuance of warrant liability in connection with financing         \$ 5         17         \$ 5           Unpaid financings issuance costs         \$ 5         17         \$ 7         \$ 5,870           Unpaid deferred offering costs         \$ 5         17         \$ —         \$ 6,5842         \$ 7,14           Unpaid deferred offering costs         \$ 15         \$ —         \$ 6,5842         \$ 7,14           Unpaid deferred offering costs         \$ 117         \$ —         \$ 6,5842         \$ 7,14           Unpaid deferred offering costs         \$ 15         \$ —         \$ 6,5842         \$ 7,14           Unpaid deferred offering costs         <		(406)			
Net cash provided by financing activities         3,917         5,898           Net decrease in cash and cash equivalents         (3,159)         2,352           Cash and cash equivalents as of beginning of period         3,330         411           Cash and cash equivalents as of end of period         \$ 171         \$ 2,763           Supplemental disclosure of cash flow information:         \$ 62         \$ 272           Cash paid for interest         \$ 117         \$ -           Cash paid for interest         \$ 117         \$ -           Capitalized acquistion costs         \$ 117         \$ -           Issuance of warrant liability in connection with financing         \$ 5         \$ 8,701           Deemed dividend on conversion of Series B preferred stock and repurchase of Series B preferred stock         \$ 5         \$ 6,842           Unpaid financings issuance costs         \$ 86         \$ 714           Unpaid deferred offering costs         \$ 117         \$ -           Reclass liability warrant to equity         \$ 15         -           Cashless exercise of warrants         \$ 5         -         \$ 87           warrant exercise in connection with loan settlement         \$ 6,333         \$ 6,333		`	(667)		
Net decrease in cash and cash equivalents         (3,159)         2,352           Cash and cash equivalents as of beginning of period         3,330         411           Cash and cash equivalents as of end of period         \$ 171         2,763           Supplemental disclosure of cash flow information:           Cash paid for interest         \$ 62         \$ 272           Noncash Investing and Financing Activities:           Capitalized acquistion costs         \$ 117         \$ -           Issuance of warrant liability in connection with financing         \$ -         \$ 8,701           Deemed dividend on conversion of Series B preferred stock and repurchase of Series B preferred stock         \$ -         \$ (5,842)           Unpaid deferred offering costs         \$ 15         \$ -           Reclass liability warrant to equity         \$ 117         \$ -           Cashless exercise of warrants         \$ 15         \$ -           Cashless exercise in connection with loan settlement         \$ 387		3.917	5.898		
Cash and cash equivalents as of beginning of period         3,30         411           Cash and cash equivalents as of end of period         \$ 171         \$ 2,763           Supplemental disclosure of cash flow information:         \$ 62         \$ 272           Cash paid for interest         \$ 62         \$ 272           Noncash Investing and Financing Activities:           Capitalized acquistion costs         \$ 117         \$ -           Issuance of warrant liability in connection with financing         \$ 3,70         \$ 8,701           Deemed dividend on conversion of Series B preferred stock and repurchase of Series B preferred stock         \$ 5         -         \$ (5,842)           Unpaid financings issuance costs         \$ 86         \$ 714           Unpaid deferred offering costs         \$ 117         \$ -           Reclass liability warrant to equity         \$ 15         -           Cashless exercise of warrants         \$ 5         -         \$ 587           warrant exercise in connection with loan settlement         \$ 333         411         \$ 5         -					
Cash and cash equivalents as of end of period         \$ 171         \$ 2,763           Supplemental disclosure of cash flow information:         \$ 62         \$ 272           Cash paid for interest         \$ 62         \$ 272           Noncash Investing and Financing Activities:           Capitalized acquistion costs         \$ 117         \$ -           Issuance of warrant liability in connection with financing         \$ -         \$ 8,701           Deemed dividend on conversion of Series B preferred stock and repurchase of Series B preferred stock         \$ -         \$ (5,842)           Unpaid deferred offering costs         \$ 15         -         \$ (5,842)           Unpaid deferred offering costs         \$ 117         \$ -         -           Reclass liability warrant to equity         \$ 15         -         -           Cashless exercise of warrants         \$ 15         -         \$ 587           warrant exercise in connection with loan settlement         \$ 333	Net decrease in cash and cash equivalents	(3,159)	2,352		
Cash and cash equivalents as of end of period         \$ 171         \$ 2,763           Supplemental disclosure of cash flow information:           Cash paid for interest         \$ 62         \$ 272           Noncash Investing and Financing Activities:           Capitalized acquistion costs         \$ 117         \$ -           Issuance of warrant liability in connection with financing         \$ .70         \$ .870           Deemed dividend on conversion of Series B preferred stock and repurchase of Series B preferred stock         \$ .70         \$ .86         714           Unpaid deferred offering costs         \$ .117         \$ .7         \$ .7           Reclass liability warrant to equity         \$ .15         \$ .7           Cashless exercise of warrants         \$ .87         \$ .87           warrant exercise in connection with loan settlement         \$ .87         \$ .87	Cash and cash equivalents as of beginning of period	3,330	411		
Cash paid for interest         \$         62         \$         272           Noncash Investing and Financing Activities:         S         117         \$         —           Capitalized acquistion costs         \$         117         \$         —           Issuance of warrant liability in connection with financing         \$         —         \$         8,701           Deemed dividend on conversion of Series B preferred stock and repurchase of Series B preferred stock         \$         5         —         \$         (5,842)           Unpaid deferred offering costs         \$         117         \$         —           Reclass liability warrant to equity         \$         15         —           Cashless exercise of warrants         \$         15         5         -           warrant exercise in connection with loan settlement         \$         5         5         587		\$ 171	\$ 2,763		
Cash paid for interest         \$         62         \$         272           Noncash Investing and Financing Activities:         S         117         \$         —           Capitalized acquistion costs         \$         117         \$         —           Issuance of warrant liability in connection with financing         \$         —         \$         (5,842)           Unpaid financings issuance costs         \$         86         \$         714           Unpaid deferred offering costs         \$         117         \$         —           Reclass liability warrant to equity         \$         15         —           Cashless exercise of warrants         \$         15         >         —           warrant exercise in connection with loan settlement         \$         35         —         \$         587					
Noncash Investing and Financing Activities:           Capitalized acquistion costs         \$ 117 \$ —           Issuance of warrant liability in connection with financing         \$         \$ .8701           Deemed dividend on conversion of Series B preferred stock and repurchase of Series B preferred stock         \$         \$         \$         \$         \$         7.14           Unpaid financings issuance costs         \$         \$         \$         \$ <td< td=""><td></td><td><u></u></td><td></td></td<>		<u></u>			
Capitalized acquistion costs  Issuance of warrant liability in connection with financing Deemed dividend on conversion of Series B preferred stock and repurchase of Series B preferred stock Unpaid financings issuance costs  Unpaid deferred offering costs  Reclass liability warrant to equity  Cashless exercise of warrants  warrant exercise in connection with loan settlement  S 17  S 2  S 86  T14  S 71  S 7  C 7  C 85  C 85  C 9  C 9  C 9  C 9  C 9  C 9  C 9  C	Cash paid for interest	\$ 62	\$ 272		
Capitalized acquistion costs  Issuance of warrant liability in connection with financing Deemed dividend on conversion of Series B preferred stock and repurchase of Series B preferred stock Unpaid financings issuance costs  Unpaid deferred offering costs  Reclass liability warrant to equity  Cashless exercise of warrants warrant exercise in connection with loan settlement  S 15  - 386  - 714  - 71  - 71  - 72  - 73  - 74  - 74  - 75	Noncash Investing and Financing Activities:				
Issuance of warrant liability in connection with financing         \$         \$         8,701           Deemed dividend on conversion of Series B preferred stock and repurchase of Series B preferred stock         \$         \$         \$         (5,842)           Unpaid financings issuance costs         \$         8         \$         714           Unpaid deferred offering costs         \$         115         \$         —           Reclass liability warrant to equity         \$         15         \$         —           Cashless exercise of warrants         \$         —         \$         587           warrant exercise in connection with loan settlement         \$         —         \$         (333)		\$ 117	s —		
Deemed dividend on conversion of Series B preferred stock and repurchase of Series B preferred stock         \$         \$         (5,842)           Unpaid financings issuance costs         \$         86         \$         714           Unpaid deferred offering costs         \$         117         \$         —           Reclass liability warrant to equity         \$         15         —         \$         587         —         \$         587         —         \$         587         —         \$         \$         587         —         \$ <td>•</td> <td>2</td> <td>\$ 8.701</td>	•	2	\$ 8.701		
Unpaid financings issuance costs         \$         86         \$         714           Unpaid deferred offering costs         \$         117         \$         -           Reclass liability warrant to equity         \$         15         \$         -           Cashless exercise of warrants         \$         -         \$         587           warrant exercise in connection with loan settlement         \$         -         \$         (333)		φ			
Unpaid deferred offering costs         \$         117         \$         —           Reclass liability warrant to equity         \$         15         \$         —           Cashless exercise of warrants         \$         —         \$         587           warrant exercise in connection with loan settlement         \$         —         \$         (333)	·	<u>s                                      </u>			
Reclass liability warrant to equity         \$ 15         \$ -           Cashless exercise of warrants         \$ 587         \$ 587           warrant exercise in connection with loan settlement         \$ (333)			\$ 714		
Cashless exercise of warrants  S = \$ 587  warrant exercise in connection with loan settlement  S = \$ (333)			<u>s</u>		
warrant exercise in connection with loan settlement	Reclass liability warrant to equity	<u>\$ 15</u>	<u>\$</u>		
The state of the s	Cashless exercise of warrants	<u>\$</u>			
Issuance of common stock in connection with Series B preferred stock \$ \$ 325	warrant exercise in connection with loan settlement	<u>\$</u>			
	Issuance of common stock in connection with Series B preferred stock	<u>\$</u>	\$ 325		

Note: Share and per share amounts have been retroactively adjusted to reflect the impact of a 1-for-150 reverse stock split effected in April 2024, as discussed in Note 1.

The accompanying notes are an integral part of these condensed consolidated financial statements.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 1. Business and Summary of Significant Accounting Policies

Datavault AI Inc., formerly known as WiSA Technologies, Inc., and before then Summit Wireless Technologies, Inc. (together with its subsidiaries also referred to herein as "we", "us", "our", "Datavault", "Datavault AI" or the "Company"), was originally formed as a limited liability company in Delaware on July 23, 2010. The Company's business is to deliver the best-in-class data management and monetization, as well as using wireless audio to transmit data and audio for consumer use. Datavault stands at the forefront of innovation, delivering cutting-edge Web 3.0 data management and high-performance computing (HPC) solutions to a global audience.

### Nasdaq Compliance

Stockholders Equity Deficiency

On July 3, 2024, the Company received a letter from the Office of General Counsel of The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with the equity requirement under Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule") as required by the Nasdaq Hearing Panel's (the "Panel") decision dated April 5, 2024 (the "April 2024 Decision").

The Panel has determined to impose a monitoring period (the "Monitor Period"), pursuant to Nasdaq Listing Rule 5815(d)(4)(B). If, during the Monitor Period, which lasts until July 3, 2025, the Nasdaq Listing Qualifications staff ("Staff") finds the Company again out of compliance with the Equity Rule, notwithstanding Nasdaq Listing Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with respect to such deficiency and Staff will not be permitted to grant additional time for the Company to regain compliance with respect to such deficiency, nor will the Company be afforded an applicable cure or compliance period pursuant to Nasdaq Listing Rule 5810(c)(3). Instead, Staff will issue a Delist Determination Letter and the Company will have an opportunity to request a new hearing with the initial Panel or a newly convened Hearings Panel if the initial Panel is unavailable. The Company will have the opportunity to respond and present to the Panel as provided by Nasdaq Listing Rule 5815(d)(4)(C). The Company's securities may at that time be delisted from Nasdaq.

### First Bid Price Deficiency

On April 29, 2024, the Company received a letter from Nasdaq notifying the Company that it has regained compliance with the Minimum Bid Price Requirement pursuant to Listing Rule 5550 (a)(2), as required by the April 2024 Decision. The Company will be subject to a mandatory panel monitor for a period of one year from the date of the letter pursuant to Nasdaq Listing Rule 5815(d)(4)(B). If, within that one-year monitoring period, the Staff finds the Company again out of compliance with the Minimum Bid Price Requirement, notwithstanding Nasdaq Listing Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with respect to that deficiency and the Staff will not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor will the Company be afforded an applicable cure or compliance period pursuant to Nasdaq Listing Rule 5810 (c)(3). Instead, the Staff will issue a delist determination letter and the Company will have an opportunity to request a new hearing with the initial Panel or a newly convened hearings panel if the initial Panel is unavailable. The one-year monitoring period has concluded.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 1. Business and Summary of Significant Accounting Policies, continued

Second Bid Price Deficiency

On May 6, 2025, the Company received a written notification (the "May 2025 Nasdaq Letter") from the Staff that it was not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth under the Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"), because the closing bid price of the Company's Common Stock was below \$1.00 per share for the previous thirty (30) consecutive business days. The May 2025 Nasdaq Letter has no immediate effect on the listing of the Common Stock, which will continue to trade uninterrupted on the Nasdaq Capital Market under the ticker "DVLT."

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted 180 calendar days from the date of the May 2025 Nasdaq Letter, or until November 3, 2025 (the "Compliance Period"), to regain compliance with the Minimum Bid Price Requirement. If at any time during the Compliance Period, the bid price of the Common Stock closes at or above \$1.00 per share for a minimum of ten (10) consecutive business days, Nasdaq will provide the Company with written confirmation of compliance with the Minimum Bid Price Requirement and the matter will be closed.

In the event the Company does not regain compliance with the Minimum Bid Price Requirement by the end of the Compliance Period, the Company may be eligible for an additional 180-calendar day grace period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and will need to provide written notice to Nasdaq of its intent to regain compliance with such requirement during such second compliance period.

If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Common Stock will be subject to delisting from the Nasdaq Capital Market.

### **Reverse Stock Splits**

### April 2024 Reverse Stock Split

On April 4, 2024, the Board approved a 1-for-150 reverse stock split (the "April 2024 Reverse Stock Split") of our outstanding shares of common stock and authorized the filing of a certificate of amendment to our certificate of incorporation, as amended, with the Secretary of State of the State of Delaware to effect the April 2024 Reverse Stock Split. On April 12, 2024, the April 2024 Reverse Stock Split was effected and the condensed consolidated financial statements have been retroactively adjusted. All common stock share numbers, warrants to purchase common stock, prices and exercise prices have been retroactively adjusted to reflect the April 2024 Reverse Stock Split. The common stock began trading on a split-adjusted basis at the start of trading on April 15, 2024. Unless otherwise indicated, the information presented in this Quarterly Report on Form 10-Q for the period ended March 31, 2025 (this "Report") gives effect to the April 2024 Reverse Stock Split.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 1. Business and Summary of Significant Accounting Policies, continued

#### **Basis of Presentation**

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position, results of operations and cash flows for the periods presented. The condensed consolidated financial statements reflect the accounts of Datavault AI Inc. and its wholly-owned subsidiaries, WISA Technologies Korea, LTD, a Korean limited company, which was established in September 2022, and WiSA, LLC, a Delaware limited liability company. All intercompany balances and transactions are eliminated.

#### Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

### Reclassification

Certain reclassifications have been made to prior periods' condensed consolidated financial statements to conform to the current period presentation. These reclassifications did not result in any change in previously reported net income (loss), total assets or stockholders' deficit.

#### Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Cash and cash equivalents are deposited in demand and money market accounts at one financial institution. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.

The Company's accounts receivable are derived from revenue earned from customers located throughout the world. The Company performs credit evaluations of its customers' financial condition and may, in certain circumstances, require full or partial payment in advance of shipping. As of March 31, 2025 and December 31, 2024, there was no allowance for credit losses. As of March 31, 2025, the Company had three customers accounting for 34%, 33% and 12% of accounts receivable. As of December 31, 2024, the Company had three customers accounting for 68%, 12% and 11% of accounts receivable. The Company had three customers accounting for 29%, 25% and 18% of its net revenue for the three months ended March 31, 2025. The Company had three customers accounting for 35%, 29% and 21% of its net revenue for the three months ended March 31, 2024.

The Company's future results of operations involve a number of risks and uncertainties. Factors that could affect the Company's future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, continued acceptance of the Company's products, competition from substitute products and larger companies, protection of proprietary technology, strategic relationships and dependence on key individuals.

The Company relies on sole-source suppliers to manufacture some of the components used in its product. The Company's manufacturers and suppliers may encounter problems during manufacturing due to a variety of reasons, any of which could delay or impede their ability to meet demand. The Company is heavily dependent on a single contractor in China for assembly and testing of its products, a single contractor in Japan for the production of its transmit semiconductor chips and a single contractor in China for the production of its receive semiconductor chips.

### **Cash and Cash Equivalents**

The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 1. Business and Summary of Significant Accounting Policies, continued

#### Accounts Receivable and Allowance for Credit Losses

Accounts receivable are recorded at the invoice amount and are generally not interest bearing. The Company reviews its trade receivables aging to identify specific customers with known disputes or collection issues. The Company exercises judgment when determining the adequacy of these reserves as it evaluates historical bad debt trends and changes to customers' financial conditions.

### Fair Value of Financial Instruments

Carrying amounts of certain of the Company's financial instruments, including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. The carrying value of the Company's borrowings and capital lease liabilities approximates fair value based upon borrowing rates currently available to the Company for loans and capital leases with similar terms. The Company's Warrant liabilities and convertible note payable are the only financial instrument that is adjusted to fair value on a recurring basis.

#### **Inventories**

Inventories, principally purchased components, are stated at the lower of cost or net realizable value. Cost is determined using an average cost, which approximates actual cost on a first-in, first-out basis. Inventory in excess of salable amounts and inventory which is considered obsolete based upon changes in existing technology is written off. At the point of loss recognition, a new lower cost basis for that inventory is established and subsequent changes in facts and circumstances do not result in the restoration or increase in the new cost basis.

### **Deferred Offering Costs**

Deferred offering costs, consisting of legal, accounting and filing fees relating to public offerings, are capitalized. The deferred offering costs will be offset against public offering proceeds upon the effectiveness of an offering. In the event that an offering is terminated, deferred offering costs will be expensed. As of March 31, 2025 and December 31, 2024, the Company had capitalized \$117,000 and \$0, respectively, of deferred offering costs in prepaid expenses and other current assets on the condensed consolidated balance sheets.

### Property and Equipment, Net

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of two to five years. Leasehold improvements and assets acquired under capital lease are amortized on a straight-line basis over the shorter of the useful life or term of the lease. Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 1. Business and Summary of Significant Accounting Policies, continued

#### **Convertible Financial Instruments**

The Company bifurcates conversion options and warrants from their host instruments and accounts for them as freestanding derivative financial instruments if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable U.S. GAAP.

When the Company has determined that the embedded conversion options and warrants should be bifurcated from their host instruments, discounts are recorded for the intrinsic value of conversion options embedded in the instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the instrument.

Debt discounts under these arrangements are amortized to interest expense using the interest method over the earlier of the term of the related debt or their earliest date of redemption.

### Warrants for Common Shares, Convertible Redeemable Preferred Shares, and Derivative Financial Instruments

Warrants for our common shares, convertible redeemable preferred shares, and derivative financial instruments are classified as equity if the contracts (1) require physical settlement or net-share settlement or (2) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). Contracts which (1) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the control of the Company), (2) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement), or (3) that contain reset provisions that do not qualify for the scope exception are classified as equity or liabilities. The Company assesses classification of its warrants for shares of common stock and other derivatives at each reporting date to determine whether a change in classification between equity and liabilities is required.

### **Product Warranty**

The Company's products are generally subject to a one-year warranty, which provides for the repair, rework, or replacement of products (at the Company's option) that fail to perform within the stated specification. The Company has assessed its historical claims and, to date, product warranty claims have not been significant. The Company will continue to assess if there should be a warranty accrual going forward.

### Revenue Recognition

The Company historically generates revenue primarily from two product categories which include the sale of Consumer Audio Products as well as the sale of Components. The Company applies the following five steps: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied. The Company considers customer purchase orders to be the contracts with a customer. Revenues, net of expected discounts, are recognized when the performance obligations of the contract with the customer are satisfied and when control of the promised goods are transferred to the customer, typically when products, which have been determined to be the only distinct performance obligations, are shipped to the customer. Expected costs of assurance warranties and claims are recognized as expense.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 1. Business and Summary of Significant Accounting Policies, continued

Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer and deposited with the relevant government authority, are excluded from revenue. Our revenue arrangements do not contain significant financing components.

Sales to certain distributors are made under arrangements which provide the distributors with price adjustments, price protection, stock rotation and other allowances under certain circumstances. The Company does not provide its customers with a contractual right of return. However, the Company accepts limited returns on a case-by-case basis. These returns, adjustments and other allowances are accounted for as variable consideration. The Company estimates these amounts based on the expected amount to be provided to customers and reduce revenue recognized. The Company believes that there will not be significant changes to our estimates of variable consideration.

If a customer pays consideration, or the Company has a right to an amount of consideration that is unconditional before the Company transfers a good or service to the customer, those amounts are classified as contract liabilities which are included in other current liabilities when the payment is made or it is due, whichever is earlier.

During the three months ended March 31, 2025 and 2024, net revenue consisted of the following:

	For the T	For the Three Months Ended March 31,			
(in thousands)	202:	5		2024	
Components	\$	492	\$	159	
Consumer Audio Products		137		96	
Total	\$	629	\$	255	

#### **Contract Balances**

The Company receives payments from customers based on a billing schedule as established in our contracts to partially offset prepayments required by our vendors on long lead time materials. Amounts collected prior to the fulfillment of the performance obligation are considered contract liabilities and classified as customer advances within accrued liabilities on the consolidated balance sheets. Contract assets are recorded when the Company has a conditional right to consideration for our completed performance under the contracts. Accounts receivables are recorded when the right to this consideration becomes unconditional. The Company has \$83,000 and \$109,000 of contract assets as of March 31, 2025 and December 31, 2024, respectively, which are recorded in Prepaids and other current assets on the condensed consolidated balance sheets. The Company expects to collect 100% of the contract assets as of March 31, 2025 in the next twelve months. During the three months ended March 31, 2025, the Company recognized \$49,000 of revenue that was included in the contract liabilities balance as of December 31, 2024.

(in thousands)	March 31, 2025	December 31, 2024
Contract Liabilities	\$ 224	\$ 174

### Revenue by Geographic Area

In general, revenue disaggregated by geography (See Note 10) is aligned according to the nature and economic characteristics of our business and provides meaningful disaggregation of our results of operations. Since we operate in one segment, all financial segment and product line information can be found in the condensed consolidated financial statements.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 1. Business and Summary of Significant Accounting Policies, continued

#### **Practical Expedients and Exemptions**

As part of our adoption of Accounting Standards Codification Topic ("ASC") 606, Revenue from Contracts with Customers, the Company elected to use the following practical expedients: (i) not to adjust the promised amount of consideration for the effects of a significant financing component when the Company expects, at contract inception, that the period between our transfer of a promised product or service to a customer and when the customer pays for that product or service will be one year or less; (ii) to expense costs as incurred for costs to obtain a contract when the amortization period would have been one year or less; and (iii) not to assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer.

In addition, the Company does not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less.

### **Stock-Based Compensation**

The Company measures and recognizes the compensation expense for restricted stock units and restricted stock awards granted to employees and directors based on the fair value of the award on the grant date.

Restricted stock units give an employee an interest in Company stock but they have no tangible value until vesting is complete. Restricted stock units and restricted stock awards are equity classified and measured at the fair market value of the underlying stock at the grant date and recognized as expense over the related service or performance period. The Company elected to account for forfeitures as they occur. The fair value of stock awards is based on the quoted price of our common stock on the grant date. Compensation cost for restricted stock units and restricted stock awards is recognized using the straight-line method over the requisite service period.

### **Research and Development**

Research and development costs are charged to operations as incurred and include salaries, consulting expenses and an allocation of facility costs.

### **Advertising Costs**

Advertising costs are charged to sales and marketing expenses as incurred. Advertising costs for the three months ended March 31, 2025 and 2024 were approximately \$146,000 and \$147,000, respectively.

### **Comprehensive Loss**

Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the three months ended March 31, 2025 and 2024, the Company's comprehensive loss is the same as its net loss.

### **Foreign Currency**

The financial position and results of operations of the Company's foreign operations are measured using currencies other than the U.S. dollar as their functional currencies. Accordingly, for these operations all assets and liabilities are translated into U.S. dollars at the current exchange rates as of the respective balance sheet date. Expense items are translated using the weighted average exchange rates prevailing during the period. Cumulative gains and losses from the translation of these operations' financial statements are reported as a separate component of stockholders' equity, while foreign currency transaction gains or losses, resulting from re-measuring local currency to the U.S. dollar are recorded in the condensed consolidated statement of operations in other income (expense), net and were not material for the three months ended March 31, 2025 and 2024.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 1. Business and Summary of Significant Accounting Policies, continued

#### **Net Loss per Common Share**

Basic and diluted net loss per common share is presented in conformity with the two-class method required for participating securities. The Company considers all series of convertible preferred stock to be participating securities. Under the two-class method, the net loss attributable to common stockholders is not allocated to the convertible preferred stock as the holders of the convertible preferred stock do not have a contractual obligation to share in the losses of the Company. Under the two-class method, net income would be attributed to common stockholders and participating securities based on their participation rights.

Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per common share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares and potentially dilutive common share equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per common share calculation, Series A 8% Senior Convertible Preferred Stock ("Series A Preferred Stock"), warrants exercisable for common stock, restricted stock units and shares issuable upon the conversion of convertible notes payable are considered to be potentially dilutive securities. Net loss is adjusted for any deemed dividends to preferred stockholders to compute income available to common stockholders.

For the three months ended March 31, 2025, warrants to purchase 15,204,647 shares of common stock, 12 shares underlying shares of restricted stock units, 1,200,000 shares underlying shares of restricted stock units issued under an inducement grant, 7,014,260 shares underlying restricted stock awards and 64,183 shares under two grants of restricted stock under inducement grants have been excluded from the calculation of net loss per common share because the inclusion would be antidilutive.

For the three months ended March 31, 2024, warrants to purchase 1,985,138 shares of common stock, 5,362 shares of restricted stock, 17 shares of restricted stock issued under an inducement grant and 14 shares underlying restricted stock units have been excluded from the calculation of net loss per common share because the inclusion would be antidilutive.

#### **Income Taxes**

Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences, and operating loss and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is "more-likely-than-not" that some portion or all of the deferred tax assets will not be realized. The Company has recognized valuation allowances against its deferred tax assets as of March 31, 2025 and December 31, 2024. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

The Company uses a comprehensive model for recognizing, measuring, presenting, and disclosing in the condensed consolidated financial statements tax positions taken or expected to be taken on a tax return. A tax position is recognized as a benefit only if it is "more-likely-than-not" that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the "more-likely-than-not" test, no tax benefit is recorded. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in tax expense. As of March 31, 2025 and December 31, 2024, the Company recognized no interest and penalties.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 1. Business and Summary of Significant Accounting Policies, continued

#### Recently Adopted Accounting Pronouncement

In December 2023, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") 2023-09 – Income Taxes (Topic 740): Improvements to Income Tax Disclosures" to help investors better understand an entity's exposure to potential changes in jurisdictional tax legislation and the ensuing risks and opportunities. Furthermore, the Update improves disclosures used to assess income tax information that affects cash flow forecasts and capital allocation decisions. The Update is effective for public business entities for annual periods beginning after December 15, 2024, on a prospective basis but does not impact interim financial statements. The Company has adopted standard as of March 31, 2025 and does not expect the adoption to have a material impact on its condensed consolidated financial statements.

### Recently Issued and Not Yet Adopted Accounting Pronouncements

ASU 2024-04 Debt—Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments: The amendments in this Update are effective for all entities for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. Early adoption is permitted as of the beginning of the annual reporting period for all entities that have adopted the amendments in Update 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

ASU 2024-03 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses: The amendments in this Update are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The interim effective date was amended by Update 2025-01 "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures: Clarifying the Effective Date" ("ASU 2025-01"), clarifying the interim reporting date when an entity must adopt ASU 2024-03. According to ASU 2025-01, ASU 2024-03 is effective for interim periods within fiscal years beginning after December 15, 2027. The Company is currently evaluating the impact of the adoption of this standard on its condensed consolidated financial statements.

The Company has reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the consolidated financial statements as a result of future adoption.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 2. Going Concern

The condensed consolidated financial statements of the Company have been prepared on a going concern basis, which contemplates the realization of assets and the discharge of liabilities in the normal course of business. As of March 31, 2025, the Company had cash and cash equivalents of \$0.2 million and reported net cash used in operations of \$6.0 million during the three months ended March 31, 2025. The Company expects operating losses to continue in the foreseeable future because of additional costs and expenses related to research and development activities, plans to expand its product portfolio, and increase its market share. The Company's ability to attain profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure.

Based on current operating levels, the Company will need to raise additional funds in the next 12 months by selling additional equity or incurring debt. To date, the Company has funded its operations primarily through sales of its securities in public and private markets, proceeds from the exercise of warrants to purchase common stock and the sale of convertible notes. Additionally, future capital requirements will depend on many factors, including the rate of revenue growth, the selling price of the Company's products, the expansion of sales and marketing activities, the timing and extent of spending on research and development efforts and the continuing market acceptance of the Company's products. These factors raise substantial doubt about the Company's ability to continue as a going concern for the twelve months from the date of this Report.

Management of the Company intends to raise additional funds through the issuance of equity securities or debt. There can be no assurance that, in the event the Company requires additional financing, such financing will be available at terms acceptable to the Company, if at all. Failure to generate sufficient cash flows from operations, raise additional capital and reduce discretionary spending could have a material adverse effect on the Company's ability to achieve its intended business objectives. As a result, the substantial doubt about the Company's ability to continue as a going concern has not been alleviated. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

### 3. Asset Purchase

On December 31, 2024, the Company completed its asset purchase of information technology assets, certain patents and trademarks (collectively, the "Acquired Assets") from EOS Technology Holdings Inc. ("EOS Holdings"). At the closing (the "DV Closing"), pursuant to that asset purchase agreement, by and between the Company and EOS Holdings, dated as of September 4, 2024, and as amended on November 14, 2024, and as further amended from time to time (the "Asset Purchase Agreement"), the Company purchased the Acquired Assets for an aggregate purchase price of approximately \$92,000,000 consisting of (i) \$10,000,000 paid in the form of a promissory note issued by the Company to EOS Holdings (the "DV Convertible Note"), and (ii) 40,000,000 shares (the "Closing Stock Consideration") of validly issued, fully paid and nonassessable shares of restricted common stock of the Company, with an aggregate fair value of approximately \$82,000,000 based on the closing stock price of the Company on December 31, 2024. EOS Holdings is considered a related party as of the DV Closing. See Note 11 Related Parties for further details.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 3. Asset Purchase, continued

#### Second Asset Purchase Agreement Amendment

In connection with but prior to the DV Closing, on December 31, 2024, the Company and EOS entered into a second amendment to the Asset Purchase Agreement (the "Second Asset Purchase Agreement Amendment"). Pursuant to the Second Asset Purchase Agreement Amendment, among other things, the parties agreed to enter into an earnout agreement (the "Earnout Agreement") instead of a royalty agreement as set forth in the Asset Purchase Agreement, and the parties agreed that EOS Holdings will only appoint one director at the DV Closing to the board of directors of the Company (the "Board"), and EOS Holdings will have the right to appoint one other director within ninety (90) days after the DV Closing. The parties also agreed that EOS Holdings will transfer at least eighty-one percent (81%) of the Closing Stock Consideration to its stockholders, and neither EOS Holdings nor any of its stockholders will own in excess of 19.99% of the number of shares of the common stock outstanding immediately after giving effect to the issuance of the Closing Stock Consideration. Pursuant to the Second Asset Purchase Agreement Amendment, EOS Holdings agreed to file a Certificate of Amendment with the Secretary of State of the State of Delaware to change its company name, and the Company agreed to file a registration statement providing for the resale by EOS Holdings of the 3,999,911 shares of common stock issued as part of the Closing Stock Consideration. Pursuant to the Second Asset Purchase Agreement Amendment, the Company caused such registration statement to become effective prior to April 15, 2025. The Company and EOS Holdings further agreed that the Company may only amend, supplement or otherwise modify the transferred liabilities.

### **Earnout Agreement**

In connection with the DV Closing, the Company and EOS Holdings entered into the Earnout Agreement, dated as of December 31, 2024, pursuant to which the Company shall pay an amount equal to three percent (3%) of the gross revenue of the Company generated from or otherwise attributable to any patents and patent applications included in the Acquired Assets, subject to customary deductions calculated in accordance with U.S. GAAP, and as further set forth in the Earnout Agreement. The earnout period commenced on the DV Closing Date and will end upon the expiration of the last to expire of the patents included in the Acquired Assets (the "Term"). The Company shall make the earnout payments to EOS Holdings on a quarterly basis during the Term.

The Earnout Agreement includes customary covenants regarding how the Company can operate its business during the term of the Earnout Agreement.

The Earnout Agreement was not assigned a fair value at the purchase date as it was not deemed likely that any payments will be made as of December 31, 2024. There is no change as of March 31, 2025.

The Company accounted for the Asset Purchase Agreement as an asset purchase in accordance with ASC 805, Business Combinations (the "Screen Test"). As such, the aggregate consideration of approximately \$92,000,000 plus capitalized fees of \$575,000 were recorded to the intangible assets acquired of patents and trademarks for \$2,384,000 and \$90,191,000, respectively, with useful weighted average remaining lives of ten years in each case. For the three months ended March 31, 2025, the amortization expense related to intangible assets was approximately \$2,309,000.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 4. Balance Sheet Components

Inventories (in thousands):

	March 31, 2025		December 31, 2024
Raw materials	\$ 35	3 \$	392
Work in progress	13	)	137
Finished goods	84	5	1,089
Total inventories	\$ 1,34	2 \$	1,618

Property and equipment, net (in thousands):

	March 31, 2025	December 31, 2024
Machinery and equipment	\$ 825	\$ 773
Tooling	14	14
	839	787
Less: Accumulated depreciation and amortization	(741)	(729)
Property and equipment, net	\$ 98	\$ 58

Depreciation expense for the three months ended March 31, 2025 and 2024 was \$12,000 and \$20,000, respectively.

#### Notes receivable

On June 13, 2024, the Company entered into a Senior Secured Promissory Note and Security Agreement ("Promissory Note and Security Agreement") with EOS Holdings ("the Borrower"). Pursuant to the Promissory Note and Security Agreement, the Company agreed to provide the Borrower with a term loan in the principal amount of \$150,000 ("June 2024 Note"). The June 2024 Note matures on October 11, 2024. Borrowings under the June 2024 Note bear interest at a rate per annum equal to 5.12%. On the maturity date, subject to any extension, the Borrower will be obligated to make a payment equal to all unpaid principal and accrued interest. On October 23, 2024, the Borrower and the Company agreed to amend the June 2024 Note maturity date to January 31, 2025. On December 31, 2024, the Borrower and the Company agreed to amend the December 2024 Note maturity date to the latter of the maturity date of the DV Convertible Note of December 31, 2027 or a qualified subsequent financing as determined by the DV Convertible Note agreement.

On August 7, 2024, the Company entered into a second Promissory Note and Security Agreement with the Borrower. Pursuant to the Promissory Note and Security Agreement, the Company agreed to provide the Borrower with a term loan in the principal amount of \$100,000 ("August 2024 Note"). The August 2024 Note matures on December 5, 2024. Borrowings under the August 2024 Note bear interest at a rate per annum equal to 5.12%. On the maturity date, subject to any extension, the Borrower will be obligated to make a payment equal to all unpaid principal and accrued interest. On October 23, 2024, the Borrower and the Company agreed to amend the August 2024 Note maturity date to January 31, 2025. On December 31, 2024, the Borrower and the Company agreed to amend the December 2024 Note maturity date to the latter of the maturity date of the DV Convertible Note of December 31, 2027 or a qualified subsequent financing as determined by the DV Convertible Note Promissory agreement.

On September 23, 2024, the Company entered into a third Promissory Note and Security Agreement with the Borrower. Pursuant to the Promissory Note and Security Agreement, the Company agreed to provide the Borrower with a term loan in the principal amount of \$73,485 (the "September 2024 Note"). The September 2024 Note matures on December 5, 2024. Borrowings under the September 2024 Note bear interest at a rate per annum equal to 5.12%. On the maturity date, subject to any extension, the Borrower will be obligated to make a payment equal to all unpaid principal and accrued interest. On October 23, 2024, the Borrower and the Company agreed to amend the September 2024 Note maturity date to January 31, 2025. On December 31, 2024, the Borrower and the Company agreed to amend the December 2024 Note maturity date to the latter of the maturity date of the DV Convertible Note of December 31, 2027 or a qualified subsequent financing as determined by the DV Convertible Note Promissory agreement.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 4. Balance Sheet Components, continued

On December 23, 2024, the Company entered into a fourth Promissory Note and Security Agreement with the Borrower. Pursuant to the Promissory Note and Security Agreement, the Company agreed to provide the Borrower with a term loan in the principal amount of \$100,000 ("December 2024 Note"). The December 2024 Note matures on January 31, 2025. Borrowings under the December 2024 Note bear interest at a rate per annum equal to 5.12%. On the maturity date, subject to any extension, the Borrower will be obligated to make a payment equal to all unpaid principal and accrued interest. On December 31, 2024, the Borrower and the Company agreed to amend the December 2024 Note maturity date to the latter of the maturity date of the DV Convertible Note of December 31, 2027 or a qualified subsequent financing as determined by the DV Convertible Note Promissory agreement.

The above notes receivable are netted on the condensed consolidated balance sheet in "convertible note payable, net related party" as of March 31, 2025 as there is a right of offset included in the DV Convertible Note and the four amended note receivable agreements above. On February 14, 2025, \$136,000 was paid off as a result of the February 2025 Offering (defined below) in which a portion of proceeds in the 2025 Offering (defined below) were used to satisfy principal on the EOS note receivables. The balance as of March 31, 2025 is \$299,000.

At March 31, 2025, the Company had recognized approximately \$5,000 of interest income on the Notes Receivable.

### **Deposits for Business Combination**

On December 19, 2024 the Company entered into an asset purchase agreement with CompuSystems Inc ("CSI") as amended on December 30, 2024, February 25, 2025 and March 31, 2025 (the "CSI Purchase Agreement") where the Company has agreed to purchase, assume and accept from CSI all of the rights, title and interests used in the acquired business, and products and services solely to the extent they utilize the transferred assets, including CSI's customer contracts, trademarks and other intellectual property (the "CSI Acquisition"). Pursuant to the CSI Purchase Agreement, the Company made an exclusivity deposit and a break-up fee deposit totaling \$2,000,000 which is recorded on the condensed consolidated balance sheet in "deposit on business combination" as of March 31, 2025. The acquisition has not closed as of March 31, 2025.

### **Accrued Liabilities**

Accrued liabilities (in thousands):

	March 31, 2025	December 31, 2024
Accrued vacation	\$ 403	\$ 407
Accrued audit fees	249	224
Accrued compensation	142	217
Contract liabilities	224	171
Accrued lease liability, current portion	111	106
Accrued other	235	209
Total accrued liabilities	\$ 1,364	\$ 1,334

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 5. Borrowings

#### January 2024 Short-Term Loan Agreement

On January 19, 2024, the Company issued promissory notes in the aggregate principal amount of \$1,000,000 (the "January 2024 Promissory Notes") and common stock purchase warrants to purchase up to an aggregate of 66,665 shares (the "January 2024 Warrant Shares") of the Company's common stock, at an initial exercise price of \$22.23 per share with four accredited investors (each an "Investor" and together the "Investors"). In connection with the January 2024 Promissory Notes, the Company received gross proceeds of \$600,000, before fees and other expenses associated with the transaction.

The January 2024 Promissory Note was to mature on the earlier to occur of: (i) July 17, 2024 and (ii) the full or partial exercise of certain Series B Preferred Stock purchase warrants currently held by the Investor, issuable for at least 9,322 shares of the Company's Series B Convertible Preferred Stock, par value \$0.0001 per share ("Series B Preferred Stock"), upon such full or partial exercise.

The January 2024 Promissory Notes did not bear interest except upon the occurrence of an Event of Default (as defined in the January 2024 Promissory Notes). The January 2024 Promissory Notes were not convertible into shares of common stock or Series B Preferred Stock.

Between the dates of January 26, 2024 and February 2, 2024, the January 2024 Promissory Notes were repaid in full following the exercise of certain of the Company's Series B Preferred Stock purchase warrants for a total of 29,322 shares of Series B Preferred Stock. The 2024 Promissory Notes were settled via the payment of \$667,000 in cash and a \$333,000 offset to the amount due by one of the investors from the exercise of 9,322 Series B Preferred Stock purchase warrants.

In connection with the issuance of the January 2024 Warrant Shares (see Note 6 – Fair Value Measurements), the fair value of the warrants and the original issue discount for interest were recorded as debt discounts totaling \$1,260,000. The debt discounts were to be amortized to interest expense over the respective term using the effective interest method. In connection with the full repayment of the January 2024 Promissory Notes, the Company recognized \$1,260,000 of interest expense in the three months ended March 31, 2024.

### DV Convertible Note

In connection with the DV Closing, the Company issued the DV Convertible Note in a principal amount of \$10,000,000 due on the third anniversary of the DV Closing on December 31, 2027. The Company agreed to pay interest to EOS Holdings on the aggregate unconverted and then outstanding principal amount of the note at the rate of five and twelve hundredths percent (5.12%) per annum, accruing from the DV Closing.

The DV Convertible Note can be converted at EOS Holding's option, partially or entirely, into shares of common stock, any time after the maturity date until the DV Convertible Note is fully paid off. The DV Convertible Note uses a conversion price equaling to seventy-five percent (75%) of the average VWAP (as defined in the DV Convertible Note) during the ten (10) consecutive trading days ending on the trading day that is immediately prior to the conversion date subject to a floor price of \$1.116 per share. At EOS Holding's sole discretion, upon a change of control (as defined in the DV Convertible Note), the Company shall (i) cause any successor entity to assume in writing all of the obligations of the Company under the DV Convertible Note, (ii) pay or cause to be paid to EOS Holdings the Note Balance (defined below) in cash, or (iii) pay, at the closing of such change of control, in full satisfaction of the Company's obligations under the DV Convertible Note, an amount in cash or equivalent common stock to the amount EOS Holdings would have been paid if it had converted its Note Balance into shares of common stock immediately prior to such closing, at the conversion price.

The parties agreed that the Company may apply up to 25% of the amount of any payment to be made to EOS Holdings pursuant to the DV Convertible Note towards satisfaction of the amount, if any, owed by EOS Holdings to the Company under those certain senior secured promissory notes, dated June 13, 2024, August 7, 2024, September 23, 2024, and December 23, 2024 (collectively, the "Secured Notes" and the outstanding amount under the Secured Notes, collectively, the "DV Holdings Note Balance"). The Note Balance on the maturity date will be automatically reduced by the amount of the DV Holdings Note Balance.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 5. Borrowings, continued

Pursuant to the DV Convertible Note, if, at any time while the DV Convertible Note is outstanding, the Company enters into any capital raising or financing transaction, including without limitation any issuance by the Company of shares of common stock or common stock equivalents (as defined in the DV Convertible Note) for cash consideration, indebtedness or a combination of units thereof (each, a "Subsequent Financing"), then the Company shall first pay to EOS Holdings at least 10% of the gross proceeds of such Subsequent Financing to redeem all or a portion of the DV Convertible Note, plus accrued but unpaid interest, plus liquidated damages, if any, and any other amounts then owing to EOS Holdings. If the aggregate gross proceeds of Subsequent Financings reach or exceed \$50,000,000, then the Company shall repay the DV Convertible Note in full, including accrued but unpaid interest, liquidated damages, if any, and any other amounts, then owing to EOS Holdings.

The DV Convertible Note includes customary event of default provisions. Upon the occurrence of an event of default, the DV Convertible Note and all amounts due thereunder shall become, upon demand by EOS Holdings, immediately due and payable in cash. Additionally, upon the occurrence of an event of default, interest shall accrue daily at the rate of ten percent (10%) per annum on the aggregate outstanding principal balance and any other amounts then owing by Company to EOS Holdings.

The Company elected the fair value method for the DV Convertible Note outstanding of \$10,000,000 as of December 31, 2024 due to the embedded derivatives identified within the agreement requiring recurring fair value measurements. The carrying value of the DV Convertible Note is the same as the fair value as of March 31, 2025 due to the note's issuance occurring on December 31, 2024 and no changes in the fair value have occurred as of the three months ended March 31, 2025. The note is valued using level 3 inputs.

On February 14, 2025, the Company paid a portion of principal and interest of \$406,000, net, as a result of the February 2025 Public Offering (defined below in Note 7) and the balance as of March 31, 2025 was \$9,582,000.

The DV Convertible Note is netted with the notes receivable from EOS Holdings in "convertible note payable, net, related party" on the condensed consolidated balance sheets as of March 31, 2025 as EOS Holdings agreed to offset the outstanding balance on the DV Convertible Note with the notes receivable at maturity or at a qualifying capital raising or financing transaction noted above.

#### 6. Fair Value Measurements

The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Each level of input has different levels of subjectivity and difficulty involved in determining fair value.

- Level 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 investments generally does not require significant judgment, and the estimation is not difficult.
- Level 2 Pricing is provided by third-party sources of market information obtained through investment advisors. The Company does not adjust for or apply any additional assumptions or estimates to the pricing information received from its advisors.
- Level 3 Inputs used to measure fair value are unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management's estimates of market participant assumptions. The determination of fair value for Level 3 instruments involves the most management judgment and subjectivity.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 6. Fair Value Measurements, continued

The Company's financial assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2025 and December 31, 2024 by level within the fair value hierarchy, are as follows:

(in thousands)		March 31, 2025	
	Quoted prices in active markets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Liabilities:			
Convertible note payable	\$	\$ —	\$ 9,582
Warrant liabilities	<u>\$</u>	\$ <u> </u>	\$ 10
(in thousands)		December 31, 2024	<u> </u>
	Quoted prices in active markets	Significant other observable inputs	Significant unobservable inputs
	(Level 1)	(Level 2)	(Level 3)
Convertible note payable	<u> </u>	<u>\$</u>	\$ 10,000
Warrant liabilities	\$ —	\$ —	\$ 664

There were no transfers between Level 1, 2 or 3 during the three months ended March 31, 2025 or 2024.

### **Warrant Liabilities**

On March 26, 2024, the Company amended the terms of certain warrant agreements to remove certain exercise price reset, right to reprice and/or share adjustment provisions ("Reset Provisions") following a reverse split, in addition to other revisions to the warrants. In April 2024, the Company effected the April 2024 Reverse Stock Split thereby removing the Reset Provisions ("Reset Amendment Effective Date") and in accordance with provisions in certain of the warrants issued warrants to purchase an additional 5,602,693 shares of common stock. Accordingly, the Company remeasured the warrant liability for each of the amended warrants following the Reset Amendment Effective Date and recorded that amount to change in fair value of warrant liabilities with a corresponding increase to warrant liabilities. Following the Reset Amendment Effective Date, such warrants were no longer deemed to be liability warrants but were now classified as equity warrants. In connection with this reclassification the Company reclassed approximately \$41.9 million from warrant liabilities to additional paid in capital.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 6. Fair Value Measurements, continued

The following table includes a summary of changes in fair value of the Company's warrant liabilities measured at fair value using significant unobservable inputs (Level 3) as of March 31, 2025 and 2024. For March 31, 2025, the fair value of the common warrants was determined using the Black-Scholes Model based on the following key inputs and assumptions: common stock price of \$0.85; exercise price of \$3.20 to \$1,574; expected yield of 0.0%; expected volatility of 163.2%; risk-free interest rate of 3.89% and expected life of 2.7 to 2.8 years.

	For t	For the three month ended March 31,		
(in thousands)	2	2025		2024
Beginning balance	\$	664	\$	5,460
Additions		_		8,701
Change in fair value		(17)		(8,129)
Exercise of warrant liabilities		_		(587)
Repurchase		(622)		(824)
Conversion of liability warrants to equity warrants		(15)		
Ending balance	\$	10	\$	4,621

The changes in fair value of the warrant liabilities are recorded in change in fair value of warrant liabilities in the condensed consolidated statements of operations.

#### **DV** Convertible Note

As described in Note 5, the Company elected the fair value option on the DV Convertible Note issued on December 31, 2024. The fair value of the note was deemed to equal the principal plus accrued interest at March 31, 2025. The Company uses level 3 inputs to measure the fair value in subsequent periods. No gain or loss was recorded on the DV Convertible Note for the three month ended March 31, 2025.

### 7. Convertible Redeemable Preferred Stock and Stockholders' Equity

February 2024 Series B Preferred Stock and Series B Preferred Stock Warrants Repurchase

On February 13, 2024, the Company and its Series B Preferred Stock and Series B Preferred Stock Warrants holders entered into an arrangement where the Company agreed to repurchase 62,657 Series B Preferred Stock shares and 81,315 Series B Preferred Stock warrants for a total of \$6,266,000. Unamortized discounts to the Series B Preferred Stock of \$5,381,000 were immediately recorded as a deemed dividend as of repurchase date. The remaining fair value of the Series B Preferred Stock Warrant Liability of \$824,000 was adjusted against additional paid-in-capital on repurchase date.

### Other Deemed Dividends

The total of deemed dividends (as discussed in this section, the Conversion of Series B Preferred Stock and February 2024 Series B Preferred Stock and Series B Preferred Stock Warrants Repurchase sections above) amounted to \$5,842,000 for the year ended December 31, 2024 and was recorded as an adjustment to net loss available to common stockholders on the Company's consolidated statement of operations.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 7. Convertible Redeemable Preferred Stock and Stockholders' Equity, continued

#### Common Stock

### February 2024 Issuance of Common Stock and Pre-Funded Common Stock Warrants

On February 13, 2024, the Company consummated a public offering (the "February 2024 Public Offering") of 158,227 units (the "February Units") and 867,373 pre-funded units (the "February Pre-Funded Units"). Each February Unit was issued at \$9.75 per unit and included one share of common stock and one common stock warrant (the "February Common Warrants") exercisable for one share of common stock at a \$9.75 exercise price. Each February Pre-Funded Unit was issued at \$9.735 per unit and included one pre-funded common stock warrant (the "February Pre-Funded Warrants"), exercisable for one share of common stock at an initial exercise price of \$0.015 and one February Common Warrant. The gross proceeds from the issuance of the February Units and the February Pre-Funded Units were \$1,543,000 and \$8,444,000, respectively, for total aggregate proceeds of \$9,987,000 before broker fees and related expenses of approximately \$998,000. As a result of certain price protection clauses, the February Common Warrants did not meet the criteria for equity classification and thus are subject to liability treatment. Accordingly, of the \$9,987,000 gross proceeds from the February 2024 Public Offering, an amount of \$6,308,000, representing the fair value of the February Common Warrants as of the issuance date was allocated to the February Common Warrants liability, with the residual proceeds of \$3,679,000 allocated to the common stock and February Pre-Funded Warrants, which met the criteria for equity classification.

Of the gross broker fees and related expenses of approximately \$998,000, the Company allocated \$368,000 to the issued common stock and February Pre-Funded Warrants, which were recorded as a reduction of additional paid-in-capital. The remaining issuance cost of \$630,000 was allocated to the February Common Warrants and was expensed on the date of issuance as such warrants were recorded at fair value.

### March 2024 Issuance of Common Stock, Prefunded Common Stock Warrants and Common Stock Warrants

On March 26, 2024, the Company entered into a Securities Purchase Agreement with certain purchasers where the Company issued 417,833 shares of common stock, 93,342 pre-funded common stock warrants (the "March Pre-Funded Warrants") and common stock warrants (the "March Common Warrants") to purchase up to 511,175 shares of common stock at an initial exercise price of \$6.00 per share (known in aggregate as the "March 2024 Offering"). Total proceeds per the Securities Purchase Agreement amounted to \$2,299,000 before broker fees and other related expenses of approximately \$388,000. As a result of certain price protection clauses, the March Common Warrants did not meet the criteria for equity classification and thus are subject to liability treatment. Accordingly, of the \$2,299,000 gross proceeds from the March public offering, an amount of \$1,227,000, representing the fair value of the March Common Warrants as of the issuance date was allocated to the March Common Warrants liability, with the residual proceeds of \$1,072,000 allocated to the common stock and March Pre-Funded Warrants, which met the criteria for equity classification.

Of the gross broker fees and related expenses of approximately \$388,000, the Company allocated \$181,000 to the issued common stock and the March Pre-Funded Warrants, which were recorded as a reduction of additional paid-in-capital. The remaining issuance cost of \$207,000 was allocated to the March Common Warrants and was expensed on the date of issuance as such warrants were recorded at fair value.

### **Warrants for Common Shares**

A summary of the warrant activity and related information for the three months ended March 31, 2025 and 2024 is provided as follows.

In connection with the January 2024 Promissory Notes, the Company issued common stock purchase warrants to investors to purchase up to 66,665 shares of the Company's common stock, at an initial exercise price of \$22.23 per share. The grant date fair value of such warrant was \$860,000, which was recorded as a liability with the offset recorded to additional paid-in capital on the consolidated balance sheets. The fair value of such warrants was determined using the Black-Scholes Model based on the following weighted average assumption: common stock price on the date of grant of \$15.99; expected yield of 0.0%; expected volatility of 119%; risk-free interest rate of 4.31% and expected life of 5 years.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 7. Convertible Redeemable Preferred Stock and Stockholders' Equity, continued

In connection with the February 2024 Public Offering, the Company issued common stock purchase warrants to investors to purchase up to 1,025,600 shares of the Company's common stock, at an initial exercise price of \$9.75 per share. The grant date fair value of such warrant was \$6,308,000, which was recorded as a liability with the offset recorded to additional paid-in capital on the consolidated balance sheets. The fair value of such warrants was determined using the Black-Scholes Model based on the following weighted average assumption: common stock price on the date of grant of \$7.62; expected yield of 0.0%; expected volatility of 119%; risk-free interest rate of 4.31% and expected life of 5 years.

In connection with the March 2024 Offering, the Company issued common stock purchase warrants to investors to purchase up to 511,175 shares of the Company's common stock, at an initial exercise price of \$6.00 per share. The grant date fair value of such warrant was \$1,227,000, which was recorded as a liability with the offset recorded to additional paid-in capital on the consolidated balance sheets. The fair value of such warrants was determined using the Black-Scholes Model based on the following weighted average assumption: common stock price on the date of grant of \$3.18; expected yield of 0.0%; expected volatility of 119%; risk-free interest rate of 4.21% and expected life of 5 years.

On March 26, 2024, the Company entered into a warrant amendment agreement (the "Warrant Amendment Agreement") with certain holders of (i) the New Common Stock Warrants, (ii) the common stock purchase warrants dated January 23, 2024 (the "January 2024 Warrants"), and (iii) the February Common Warrants (together with the New Common Stock Warrants and the January 2024 Warrants, the "Original Warrants"), whereby the holders agreed to (i) amend the New Common Stock Warrants and the January 2024 Warrants so such warrants shall not be exercisable until one or more certificates of amendment to the Company's certificate of incorporation, as amended, are filed with the Secretary of State of the State of Delaware to effectuate an increase in authorized shares of capital stock of the Company and a reverse stock split of the Company's outstanding shares of common stock; and (ii) remove certain exercise price reset, right to reprice and/or share adjustment provisions in the Original Warrants, to be effective following the first adjustments following the April 2024 Reverse Stock Split.

### February 2024 Warrants Black Scholes Value Payout

On December 31, 2024 on the closing of the DV Asset Acquisition, a provision requiring a Black Scholes Value payout was triggered in the remaining outstanding February 2024 Warrants. This provision was triggered because the DV Asset Acquisition met the criteria for a fundamental change as described in the warrant agreement. The Black Scholes Value payout was valued at \$1.96 per share and there was an aggregate number of warrants outstanding of 328,483. In order to receive the payout, holders must elect within 30 days of the fundamental change otherwise the warrants convert to warrants in the Company. The warrants were equity classified prior to the close of the DV Asset Acquisition and were reclassified to liability treatment as a result of the payout liability on December 31, 2024. In the three months ended March 31, 2025, 316,415 warrants received requests from the holders to receive the Black Scholes Value payout and thus were paid in cash \$622,000 with the remaining unrequested warrants being reclassified to equity treatment as the January 30, 2025 deadline passed and they reverted to equity warrants. The Company recognized a gain of \$8,000 as a result of reclassifying the warrants to equity.

### February 2025 Registered Direct Transaction

On February 14, 2025, the Company closed an offering (the "February 2025 Offering") pursuant to a securities purchase agreement (the "February 2025 Purchase Agreement") with certain investors (the "February 2025 Investors"). In the February 2025 Offering, the Company issued and sold to the February 2025 Investors in a registered direct offering, (a) an aggregate of 4,757,126 shares (the "February 2025 Shares") of common stock of the Company, and (b) common stock purchase warrants (the "February 2025 Warrants", and together with the Shares, the "February 2025 Securities") exercisable for an aggregate of up to 4,757,126 shares of common stock, at an exercise price of \$1.14 per share (the "February 2025 Warrant Shares") at a combined offering price of \$1.14 per share and accompanying February 2025 Warrant, for aggregate gross proceeds of approximately \$5.4 million.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 7. Convertible Redeemable Preferred Stock and Stockholders' Equity, continued

The February 2025 Warrants are immediately exercisable upon issuance and will expire on the fifth anniversary of the issuance date of the February 2025 Warrants. The February 2025 Warrants may be exercised, in certain circumstances, on a cashless basis pursuant to the formula contained in the February 2025 Warrants.

The grant date fair value of the 4,757,126 warrants was approximately \$5,257,000, which were treated as equity instruments. The fair value of such warrants was determined using the Black-Scholes Model based on the following weighted average assumption: common stock price on the date of grant of \$1.22; expected yield of 0%; expected volatility of 143.4%; risk-free interest rate of 4.3% and expected life of 5 years.

Obligations Under the Purchase Agreement

Pursuant to the February 2025 Purchase Agreement, the Company agreed, subject to certain exceptions, (i) not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of its shares of common stock or securities convertible into common stock until 30 days after the closing date of the February 2025 Offering, and (ii) not to issue certain securities if the issuance would constitute a variable rate transaction for a period of 4 months from the closing date of the February 2025 Offering, in each case unless the Company is required to complete a financing prior to the applicable date in order to satisfy Nasdaq's continued listing requirements.

Placement Agency Agreement

In connection with the February 2025 Offering, on February 13, 2025, the Company entered into a placement agency agreement (the "February 2025 Placement Agency Agreement") with Maxim Group LLC (the "February 2025 Placement Agent"), pursuant to which the February 2025 Placement Agent agreed to act as placement agent on a "reasonable best efforts" basis in connection with the February 2025 Offering. Pursuant to the February 2025 Placement Agent an aggregate fee equal to 7.0% of the gross proceeds raised in the February 2025 Offering and reimburse the February 2025 Placement Agent an amount up to \$75,000 for expenses in connection with the February 2025 Offering. The Company also issued the February 2025 Placement Agent a private warrant (the "February 2025 Placement Agent Warrant") to purchase up to 5.0% of the aggregate number of February 2025 Securities sold in the February 2025 Offering, or warrants to purchase up to 475,713 shares of common stock (such shares, the "February 2025 Placement Agent Warrant Shares"), at an exercise price equal to 125.0% of the offering price per share of common stock and accompanying February 2025 Warrant, or \$1.425 per share. The February 2025 Placement Agent Warrants will be exercisable 6 months after the commencement of sales in the February 2025 Offering and will expire on the five year anniversary of the initial exercise date.

During the three months ended March 31, 2025, two holders of warrants executed their right under the "alternative cashless exercise" provision to effect a cashless exercise of a total of 3,246,111 shares of common stock.

Warrants exercisable as of March 31, 2025 exclude warrants to purchase 1 shares of common stock issued to a marketing firm, which vest upon the achievement of certain milestones, warrants to purchase 2,513,703 shares of common stock issued to investors that participated in the December Inducement Agreement and warrants to purchase 607,689 shares of common stock issued to investors that participated in the September Inducement Agreement that requires shareholder approval prior to the warrants being exercisable, warrants to purchase 475,713 shares of common stock issued to the Placement Agents (defined below in Note 13) and warrants to purchase 12,068 shares of common stock issued to investors that participated in the February 2024 Public Offering that requires shareholder approval prior to the warrants being exercisable.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 7. Convertible Redeemable Preferred Stock and Stockholders' Equity, continued

Information regarding warrants for common stock outstanding and exercisable as of March 31, 2025 is as follows:

Exercise Price	Warrants Outstanding as of March 31, 2025	Weighted Average Remaining Life (years)	Warrants Exercisable as of March 31, 2025
\$1.14 - \$2.21	14,259,408	5.7	10,650,235
\$3.18 - \$3.48	618,617	4.1	618,617
\$5.06 - \$6.00	320,559	4.1	320,559
\$1,574.00 - \$30,000.00	5,860	2.8	5,860
\$38,250.00 - \$262,500.00	203	0.3	203
\$3.17 *	15,204,647	_	11,595,474

Weighted average

Information regarding warrants for common stock outstanding and exercisable as of December 31, 2024 is as follows:

Exercise Price	Warrants Outstanding as of December 31, 2024	Weighted Average Remaining Life (years)	Warrants Exercisable as of December 31, 2024
\$1.83 - \$2.21	12,589,095	3.9	9,746,909
\$3.18 - \$3.48	618,617	7.0	618,617
\$5.06 - \$6.00	320,559	7.3	320,559
\$1,574.00 - \$30,000.00	5,860	3.0	5,860
\$38,250.00 - \$262,500.00	203	0.6	202
\$3.87*	13,534,334	4.1	10,692,147

<sup>\*</sup> Weighted average

Warrants exercisable as of December 31, 2024 exclude warrants to purchase 1 share of common stock issued to a marketing firm, which vest upon the achievement of certain milestones, warrants to purchase 2,513,703 shares of common stock issued to investors that participated in the December Inducement Agreement that requires shareholder approval prior to the warrants being exercisable and warrants to purchase 328,483 shares of common stock issued to investors that participated in the February 2024 Public Offering that requires shareholder approval prior to the warrants being exercisable, for which all have been recorded as a liability due to the triggering with the Datavault Transaction of the Black Scholes Value payout provision.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 8. Stock-Based Compensation

#### 2018 Long Term Stock Incentive Plan

On January 30, 2018, the Company's board of directors approved the establishment of the Company's 2018 Long-Term Stock Incentive Plan (the "LTIP") and termination of its Carve-Out Plan. Under the LTIP, the aggregate maximum number of shares of common stock (including shares underlying options) that may be issued under the LTIP pursuant to awards of Restricted Shares or Options will be limited to 15% of the outstanding shares of common stock, which calculation shall be made on the first trading day of each new fiscal year; provided that, in any year no more than 8% of the common stock or derivative securitization with common stock underlying 8% of the common stock may be issued in any fiscal year. At a Special Meeting of Stockholders on January 24, 2023, the Company's stockholders approved certain amendments to the LTIP to: (i) increase the annual share limit of common stock that may be issued in any single fiscal year only for the 2023 fiscal year under the LTIP from 8% of the shares of common stock outstanding to 15% of the shares of common stock outstanding (which amount equates to the maximum amount that may be issued in the aggregate under the LTIP), and (ii) permit immediately quarterly calculations based on the number of shares of common stock outstanding as of the first trading day of each fiscal quarter, rather than solely as of the first trading day of the fiscal year. At a Special Meeting of Stockholders on March 15, 2024, the Company's stockholders further approved an amendment to the LTIP to increase the annual share limit of common stock that may be issued only for the 2024 fiscal year under the LTIP from 8% of the shares of common stock outstanding to 15% of the shares of common stock outstanding (which amount equates to the maximum amount that may be issued in the aggregate under the LTIP). At the annual meeting of stockholders held on December 20, 2024 stockholders voted to remove the annual share limit of common stock that may be issued for a certain fiscal year under the LTIP. As a result of this change, the maximum number of shares of common stock that may be subject to equity awards is limited to 15% of the shares of common stock outstanding, which calculation is made using the number of common stock outstanding as of the first trading day of each fiscal quarter. As of March 31, 2025, up to 3,303,983 shares of common stock are available for grants to participants under the LTIP.

A summary of activity related to restricted stock awards with service-based vesting conditions for the three months ended March 31, 2025 is presented below.

Stock Awards	Shares	ed-Average ate Fair Value
Non-vested as of January 1, 2025	669,344	\$ 3.08
Granted	4,165,338	\$ 1.04
Vested	(56,591)	\$ 3.56
Forfeited	(133,445)	\$ 1.74
Non-vested as of March 31, 2025	4,644,646	\$ 1.21

A summary of activity related to restricted stock awards with performance-based vesting conditions for the three months ended March 31, 2025 is presented below:

\*\*\* \* 1 4 1 4

Stock Awards	Shares	1-Average e Fair Value
Non-vested as of January 1, 2025		\$ _
Granted	1,955,000	\$ 1.04
Vested	_	\$ _
Forfeited		\$ _
Non-vested as of March 31, 2025	1,955,000	\$ 1.04

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 8. Stock-Based Compensation, continued

As of March 31, 2025, the unamortized compensation costs related to the unvested restricted stock awards with service based vesting conditions was approximately \$5,609,000 which is to be amortized on a straight-line basis over a weighted-average period of approximately 2.8 years. As of March 31, 2025, the unamortized compensation costs related to the unvested restricted stock awards with performance based vesting criteria was \$1,930,000 which is to be amortized on a straight-line basis over a weighted-average period of approximately 1.7 years. These performance awards vest upon the achievement of the Company's aggregate revenue equaling or exceeding \$40,000,000 over a trailing 12 calendar month period ending on or prior to the date that is 5 years from the grant date. The performance awards are assigned a 100% probability to achieve the performance conditions.

For the three months ended March 31, 2025, no shares of restricted stock units were released under the LTIP. For the three months ended March 31, 2024, 20 shares of restricted stock issued under the LTIP, were released.

### **Inducement Grants**

On September 13, 2021, Eric Almgren joined the Company as Chief Strategist and was issued 21 shares of restricted common stock as an inducement grant ("September 2021 Inducement Grant"). As of March 31, 2025, all compensation cost related to the September 2021 Inducement Grant was expensed. As of March 31, 2025, 16 shares are unvested.

On September 30, 2024, the Company issued 70,000 shares of restricted common stock at a fair value per share of \$1.77, to Stanley Mbugua, the Company's Chief Accounting Officer, as an inducement grant ("September 2024 Inducement Grant") pursuant to an inducement award agreement dated as of the same date. Due to the Company closing the acquisition of Data Vault on December 31, 2024, the September 2024 Inducement Grant vesting was fully accelerated due to the change in control that occurred. As of March 31, 2025, there is no unamortized compensation cost related to the September 2024 Inducement Grant.

On January 2, 2025, the Company issued 1,200,000 units of restricted stock at a fair value per share of \$2.04, to Nathaniel Bradley, Chief Executive Officer, as an inducement grant (the "Bradley Inducement Grant") pursuant to an inducement award agreement dated December 31, 2024. Of this grant, 600,000 units have service-based conditions and vest in 3-month equal installments over a 36-month period, while the other 600,000 units have performance based condition and vest upon the Company's aggregate revenue equaling or exceeding \$40,000,000 over trailing 12 calendar month period ending on or prior to the date that is 5 years from the grant date. As of March 31, 2025, the unamortized compensation cost related to the Bradley Inducement Grant was approximately \$2,255,000 which is being amortized on a straight-line basis over a period of 2.25 years.

### 2022 Plan

A summary of activity related to restricted stock units under the Company's Technical Team Retention Plan of 2022 (the "2022 Plan") for the three months ended March 31, 2025 is presented below:

Stock Units	Shares	eighted-Average nt Date Fair Value_
Non-vested as of January 1, 2025	14	\$ 6,407
Granted	_	\$ _
Vested	(2)	\$ 6,500
Forfeited	_	\$ _
Non-vested as of March 31, 2025	12	\$ 6,392

As of March 31, 2025, the unamortized compensation cost related to the unvested restricted stock units was approximately \$58,000 which is to be amortized on a straight-line basis over a weighted-average period of approximately 1.2 years.

For the three months ended March 31, 2025, no shares of restricted stock units were released under the 2022 Plan. For the three months ended March 31, 2024, 3 shares of restricted stock units were released under the 2022 Plan.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 9. Income Taxes

The Company recorded no provision for income taxes for the three months ended March 31, 2025 and 2024.

For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company also computes the tax provision or benefit related to items reported separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company also recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur.

As of March 31, 2025 and December 31, 2024, the Company retains a full valuation allowance on its deferred tax assets. The realization of the Company's deferred tax assets depends primarily on its ability to generate taxable income in future periods. The amount of deferred tax assets considered realizable in future periods may change as management continues to reassess the underlying factors it uses in estimating future taxable income.

The provision for income taxes for the three months ended March 31, 2025 and 2024 was calculated on a jurisdiction basis.

### 10. Commitments and Contingencies

### **Operating Leases**

The Company leases office space under a non-cancellable operating lease that expires in January 2024 and has an option to renew this lease, with renewal rates to be negotiated. Operating lease rentals are expensed on a straight-line basis over the life of the lease beginning on the date we take possession of the property. At lease inception, we determine the lease term by assuming the exercise of those renewal options that are reasonably assured. The exercise of lease renewal options is at our sole discretion. The lease term is used to determine whether a lease is financing or operating and is used to calculate straight-line rent expense. Additionally, the depreciable life of leasehold improvements is limited by the expected lease term. Leases with an initial term of 12 months or less are not recorded on the condensed consolidated balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term.

The following table reflects our lease assets and our lease liabilities at March 31, 2025 and December 31, 2024 (in thousands):

	M	March 31, 2025				
Assets:						
Operating lease right-of-use assets	\$	515	\$	536		
Liabilities:						
Operating lease liabilities, current	\$	111	\$	106		
Operating lease liabilities, non-current	\$	523	\$	553		

Operating lease right-of-use assets are included in other assets. Operating lease liabilities, current, are included in accrued liabilities and Operating lease liabilities, non-current, are include in other liabilities on the condensed consolidated balance sheets.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 10. Commitments and Contingencies, continued

### **Lease Costs:**

The components of lease costs were as follows (in thousands):

	Marc	March 31, 2025		rch 31, 2024
Operating lease cost	\$	47	\$	53
Short term lease cost		8		8
Total lease cost	\$	55	\$	61

As of March 31, 2025, the maturity of operating lease liabilities was as follows (in thousands):

Payments due in:	
Year ending December 31, 2025 (9 months remaining)	\$ 138
Year ending December 31, 2026	189
Year ending December 31, 2027	194
Year ending December 31, 2028	200
Year ending December 31, 2029	103
Total minimum lease payments	 824
Less: Amounts representing interest	(190)
Present value of capital lease obligations	\$ 634

### Lease Term and Discount Rate:

	March 31, 2025
Weighted-average remaining lease term (in years)	4.25
Weighted-average discount rate	13.0 %

The discount rate was calculated by using the Company's estimated incremental borrowing rate.

### Other Information:

Supplemental cash flow information related to leases was as follows (in thousands):

	 March 31, 2025
Operating cash outflows from operating leases	\$ 45

### Contingencies

In the normal course of business, the Company may become involved in legal proceedings. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of a possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred.

The Company's management does not believe that any such matters, individually or in the aggregate, will have a materially adverse effect on the Company's condensed consolidated financial statements.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 11. Related Parties

### Nathaniel Bradley and EOS Holdings

Nathaniel Bradley, the Chief Executive Officer ("CEO") of the Company, is a control person of EOS Holdings which became a related party of the Company at the close of the DV Asset Acquisition on December 31, 2024. In addition, Sonia Choi, the Company's Chief Marketing Officer is the spouse of the Company's CEO and holds the position of Chief Marketing Officer of EOS Holdings, a related party of the Company. EOS Holdings received 3,999,911 shares of common stock of the Company at the close of the transaction. As described in Note 5 Borrowings, the Company owes \$9.7 million of principal balance under the DV Convertible Note to EOS Holdings, and EOS Holdings owes \$299,000 in notes receivable to the Company, as of March 31, 2025. The Company has recorded \$5,000 in interest income on the notes receivable for the year ended March 31, 2025.

In addition to the DV Convertible Note and the Data Vault Note Balance, on January 16, 2025, the Company entered into a Transition Services Agreement ("Transition Services Agreement") to receive from EOS Holdings, employees to provide transition services in connection with the Acquired Assets for a period of up to three months. For the period from January 16, 2025 through March 31, 2025, the Company has paid \$428,000 to EOS Holdings.

### Helge Kristensen

Mr. Kristensen has served as a member of the Company's board of directors since 2010. Mr. Kristensen serves as vice president of Hansong Technology, an original device manufacturer of audio products based in China, president of Platin Gate Aps, a company with focus on service-branding in lifestyle products as well as pro line products based in Denmark and co-founder and director of Inizio Capital, an investment company based in the Cayman Islands.

For the three months ended March 31, 2025 and 2024, Hansong Technology purchased modules from the Company of approximately \$11,000 and \$25,000, respectively, and made no payments to the Company during those same periods. At March 31, 2025 and 2024, Hansong Technology owed the Company approximately \$35,000 and \$29,000, respectively.

For the three months ended March 31, 2025 and 2024, Hansong Technology sold no speaker products to the Company, and the Company made no payments to Hansong Technology for the three months ended March 31, 2025 and approximately \$25,000 for the three months ended March 31, 2024. At March 31, 2025 and 2024, the Company owed Hansong Technology approximately \$43,000 and \$225,000, respectively.

As of March 31, 2025 and December 31, 2024, Mr. Kristensen owned less than 1.0% of the outstanding shares of the Company's common stock.

### 12. Segment Information

The Company has adopted ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures and has revised prior year disclosures to conform with the current year presentation. The Company operates in one business segment. Our chief decision-maker, the President and Chief Executive Officer, evaluates our performance based on company-wide consolidated results.

Operating segments have been identified based on the financial information utilized by the Company's Chief Executive Officer, the chief operating decision maker ("CODM"). The CODM uses net income as a measure of profitability to assess segment performance and deciding on how to allocate resources such as capital investments, share repurchases, and acquisitions. The CODM does not use or receive total assets by segment to make decisions regarding resources; therefore, the total asset disclosure by segment has not been included.

The Company operates in one business segment. Our chief decision-maker, the Chief Executive Officer, evaluates our performance based on company-wide consolidated results.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 12. Segment Information continued

The following table reflects results of operations of the Company's reportable segment (in thousands):

	Three months ended March 31, 2025	Three months ended March 31, 2024
Net revenue	\$ 629	\$ 255
Cost of net revenue	560	338
Salaries, benefits, and stock based compensation expense	3,558	2,284
Other segment expenses	3,621	1,771
Depreciation and amortization expense	2,321	20
Interest (expense), net	(120)	(1,265)
Other (expense) income, net	(12)	8,130
Income tax expense		
Net (loss) income	\$ (9,563)	\$ 2,707

Net revenue from customers is designated based on the geographic region to which the product is delivered. Net revenue by geographic region for the three months ended March 31, 2025 and 2024 was as follows:

	For th	March 31,			
(in thousands)	2025			2024	
Asia Pacific	\$	365	\$	88	
North America		137		87	
Europe		127		80	
Total	\$	629	\$	255	

Substantially all of our long-lived assets are located in the United States.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 13. Subsequent Events

#### Securities Purchase Agreement

On April 3, 2025, the Company completed the initial closing of its previously announced transaction (the "April 2025 Offerings") in which, pursuant to a securities purchase agreement (the "April 2025 Purchase Agreement") between the Company and certain institutional investors (the "April 2025 Purchasers"), dated March 31, 2025, the April 2025 Purchasers agreed to purchase from the Company (a) in a registered direct offering, senior secured convertible notes having an aggregate principal amount of \$5,555,555 (the "Initial Notes") for an aggregate purchase price of \$5,000,000 and senior secured convertible notes having an aggregate principal amount of \$11,111,111 (the "Additional Notes", and together with the Initial Notes, the ("2025 Notes") for an aggregate purchase price of \$10,000,000 upon satisfaction of certain closing conditions applicable to the Initial Notes and Additional Notes, respectively and (b) in a concurrent private placement, common stock purchase warrants ("2025 Warrants") to purchase up to 19,346,101 shares of common stock of the Company, of which warrants to purchase up to 6,448,700 shares of common stock were issued in connection with the issuance of the Initial Notes (the "April 2025 Initial Warrants") and warrants to purchase up to 12,897,401 shares of common stock will be issued in connection with the issuance of the Additional Notes (the "Additional Warrants").

The closing of the Additional Notes and Additional Warrants (the "Additional Closing," and together with the initial closing, the "2025 Closings") will take place on or after the date that is 20 days after the mailing by the Company of a definitive information statement on Schedule 14(c) with respect to the approval, by written consent of the Company's stockholders, of the issuance of the shares of common stock issuable upon conversion of the 2025 Notes and exercise of the 2025 Warrants and a one-time reset, at the Company's option, of the exercise price of outstanding common stock purchase warrants held by the April 2025 Purchasers that do not contain "alternative cashless exercise" features ("Stockholder Approval").

Pursuant to the April 2025 Purchase Agreement, until the date that is 18 months after the date on which the 2025 Notes are no longer outstanding, the April 2025 Purchasers have the right, but not the obligation, to participate in any issuance by the Company of any debt, preferred stock, shares of common stock or securities convertible into shares of common stock (a "Subsequent Financing") up to a maximum of 65% of such Subsequent Financing on the same terms, conditions and price provided to other investors in such Subsequent Financing.

### Notes

The 2025 Notes carry a 10% original issue discount, and mature 18 months from the date of issuance. No interest accrues during the term of the 2025 Notes, unless an event of default occurs, in which case interest will accrue at a rate of 12% per annum. The obligations under these 2025 Notes rank senior to all other existing indebtedness and equity of the Company. The 2025 Notes are convertible into shares of the Company's common stock at any time beginning on the date of Stockholder Approval at the option of the holders thereof, in whole or in part, into such number of shares of common stock (the "Conversion Shares") at an initial conversion price equal to \$1.00 per share (the "Conversion Price"). Alternatively, the Notes are convertible at a price (the "Alternate Conversion Price") equal to the greater of (x) the Floor Price (as defined below) and (y) 90% of the lowest volume weighted adjusted price of the shares of Common Stock (the "VWAP") in the ten (10) trading days prior to the applicable conversion date ("Alternate Conversions").

The conversion price of the 2025 Notes is subject to a floor price of \$0.1794 (the "Floor Price").

In the event the Alternate Conversion Price would be lower than the Floor Price, the Company is required to compensate the holders of the 2025 Notes by paying the holders in cash an amount (the "Alternate Conversion Floor Amount") equal to the product obtained by multiplying (A) the VWAP on the day the holder delivers the applicable conversion notice and (B) the difference obtained by subtracting (I) the number of shares of common stock delivered (or to be delivered) to the holder on the applicable share delivery date with respect to such Alternate Conversion from (II) the quotient obtained by dividing (x) the applicable conversion amount that the holder has elected to be the subject of the applicable Alternate Conversion, by (y) the applicable Alternate Conversion Price without being limited by the Floor Price.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 13. Subsequent Events, continued

Under the 2025 Notes, the Company is required to use up to 30% of the proceeds from future financings to redeem the 2025 Notes in an amount equal to the aggregate principal amount of the 2025 Notes being redeemed from such proceeds multiplied by 105%. The 2025 Notes contain 4.99/9.99% beneficial ownership limitations and customary provisions regarding events of defaults and negative covenants.

### Warrants

The 2025 Warrants have an initial exercise price of \$0.8615 per share. The Initial Warrants will be exercisable upon effectiveness of Stockholder Approval and expire five (5) years from the date of such effectiveness. The Additional Warrants will be issued in the Additional Closing, exercisable immediately upon issuance and expire five (5) years from the date of issuance. The exercise price of the 2025 Warrants is subject to (a) downward adjustment in the event the Company issues shares of common stock or common stock equivalents having an effective price lower than the then current exercise price of the 2025 Warrants, subject to certain exceptions and (b) standard, proportional adjustments in the event of certain events, such as stock splits, combinations, dividends, distributions, reclassifications, mergers or other corporate changes. The Warrants contain 4.99/9.99% beneficial ownership limitations.

### Security Agreement and Guarantee

In connection with the initial closing on April 3, 2025, the Company entered into (i) a security agreement (the "Security Agreement"), which grants to the holders of the Notes a security interest in all of the assets of the Company, and (ii) a subsidiary guarantee (the "Subsidiary Guarantee"), pursuant to which all domestic subsidiaries of the Company have guaranteed the Company's obligations under the Notes.

### Placement Agency Agreement

As previously announced, in connection with the April 2025 Offerings, the Company entered into a placement agency agreement (the "April 2025 Placement Agency Agreement") with Maxim Group LLC (the "Placement Agent") on March 31, 2025, pursuant to which the Placement Agent agreed to act as placement agent on a "reasonable best efforts" basis in connection with the April 2025 Offerings. Pursuant to the April 2025 Placement Agency Agreement and in connection with initial closing, the Company paid the Placement Agent an aggregate fee equal to 8.0% of the gross proceeds raised at the initial closing and reimbursed the Placement Agent an amount up to \$15,000 for expenses in connection with the Offerings.

In addition to similar rights previously granted to the Placement Agent, pursuant to the Placement Agency Agreement, the Company granted the Placement Agent a right of first refusal for a period of 30 days from August 22, 2025 to provide investment banking services to the Company on an exclusive basis, exercisable in the Placement Agent's discretion. Under the Placement Agency Agreement, for a period of nine (9) months from the Initial Closing, the Company will pay the Placement Agent a cash fee equal to 7.0% of the gross proceeds of any capital raising activity received by the Company from the Purchasers in the Offerings.

### NYIAX Agreements

### Exchange Agreement

On March 16, 2025, the Company entered into a share exchange agreement (the "Exchange Agreement") with NYIAX, Inc., a Delaware corporation ("NYIAX"), pursuant to which NYIAX exchanged 900,000 shares (the "NYIAX Shares") of NYIAX's common stock, par value \$0.0001 per share (the "NYIAX Common Stock"), for aggregate consideration of up to 5,000,000 shares of common stock (collectively, the "Exchange"). The Exchange Agreement was not closed as of March 31, 2025.

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 13. Subsequent Events, continued

Pursuant to the Exchange Agreement, as full consideration for the sale, assignment, transfer and delivery of the NYIAX Shares by NYIAX to the Company, and upon the terms and subject to all of the conditions contained in the Exchange Agreement, the Company agreed to issue to NYIAX (i) 3,000,000 shares of common stock (such shares of common stock, the "Closing Shares"), and (ii) 2,000,000 shares of common stock (such shares of common stock, the "Additional Shares"), upon the terms and subject to the conditions set forth in the Exchange Agreement. The Closing Shares will be issued in four equal quarterly transhes starting from the closing.

The Additional Shares will be issued only upon completion of a complete advertising cycle for a third party clientele, and upon the parties' mutual written agreement that the Adio Platform (as defined in the Exchange Agreement) has been integrated into the NYIAX Platform (as defined in the Exchange Agreement) upon completion of the advertising cycle. The Additional Shares will be issued within thirty (30) days from the completion of the integration.

The Exchange Agreement includes customary representations and warranties and various customary covenants and closing conditions that are subject to certain limitations, including, without limitation, certain agreements.

Intellectual Property Cross-License Agreement

In connection with the Exchange, on March 16, 2025, the Company entered into a white label, co-marketing and intellectual property cross-license agreement (the "License Agreement") with NYIAX, pursuant to which the Company received a non-exclusive license under certain of NYIAX's jointly owned patent rights and know-how, and a non-exclusive license to white label NYIAX's proprietary software-as-a-service advertising brokerage platform, all within the field of data, information and asset monetization and exchange. In exchange, the Company granted to NYIAX a non-exclusive license under certain of the Company's wholly owned patent rights, know-how and trademarks, including with respect to the Company's Adio Platform (as defined in the License Agreement), in the field of advertising buying, selling and brokerage.

Pursuant to the License Agreement, as consideration for the services provided by NYIAX pursuant to the License Agreement and the rights to access and use the NYIAX Platform (as defined in the License Agreement) granted to the Company, and upon the terms and subject to all of the conditions contained in the License Agreement, the Company agreed to issue to NYIAX 2,530,000 shares (such shares, the "Consideration Shares") of common stock.

Pursuant to the License Agreement, in consideration of the rights granted to NYIAX under the License Agreement, NYIAX agreed to pay to the Company a license fee in the form of a convertible promissory note in the aggregate amount \$2,500,000 (the "NYIAX Convertible Note"). The NYIAX Convertible Note is due on the first anniversary of the closing (the "Maturity Date"). NYIAX agreed to pay interest to the Company on the aggregate unconverted and then outstanding principal amount of the NYIAX Convertible Note at the rate of four percent (4%) per annum, accruing from the closing. The NYIAX Convertible Note may be prepaid in full at NYIAX's election.

The NYIAX Convertible Note will automatically convert at the earlier of (i) the Maturity Date, and (ii) the first underwritten public offering of NYIAX pursuant to an effective registration statement under the Securities Act, covering the offer and sale by NYIAX of its equity securities, as a result of or following which NYIAX shall be a reporting issuer under the Exchange Act, and NYIAX's common stock is listed on the Trading Market (as defined in the NYIAX Convertible Note), at a conversion price of \$2.00 per share.

The License Agreement includes customary representations and warranties and various customary covenants and closing conditions that are subject to certain limitations, including, without limitation, certain agreements.

# DATAVAULT AI INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2025 and 2024 (unaudited)

### 13. Subsequent Events, continued

Software Development Agreement

In connection with the Exchange, on March 16, 2025, the Company entered into a software development agreement (the "Software Development Agreement") with NYIAX, pursuant to which NYIAX has engaged the Company to develop certain software and provide certain additional professional services as the parties will agree under one or more statements of work.

The Software Development Agreement includes customary representations and warranties and various customary covenants and closing conditions that are subject to certain limitations, including, without limitation, certain agreements.

#### Lock-up Agreements

On April 9, 2025, the Company and NYIAX entered into the Lock-Up Agreements (defined below). In connection with the Exchange Agreement, the Company agreed to enter into a lock-up agreement in respect of the NYIAX Shares, pursuant to which the NYIAX Shares shall be subject to lock-up restrictions for four (4) years from the issuance (the "Datavault Lock-Up Agreement). Concurrently, NYIAX agreed to enter into (i) a lock-up agreement in respect of the Additional Shares to be issued by the Company to NYIAX pursuant to the Exchange Agreement, pursuant to which the Additional Shares shall be subject to lock-up restrictions for two (2) years from the issuance (the "Additional Lock-Up Agreement"), (ii) a lock-up agreement in respect of the consideration shares (the "Consideration Shares") to be issued by the Company to NYIAX pursuant to that certain White Label, Co-Marketing and Intellectual Property Cross-License Agreement, by and between the Company and NYIAX, dated as of March 16, 2025, pursuant to which the Consideration Shares shall be subject to lock-up restrictions for one (1) year from the issuance (the "Consideration Lock-Up Agreement"), and (iii) a lock-up agreement in respect of the Closing Shares to be issued by the Company to NYIAX pursuant to the Exchange Agreement, pursuant to which the Closing Shares shall be subject to lock-up restrictions for one (1) year from the issuance (the "Closing Lock-Up Agreement"), and together with the Datavault Lock-Up Agreement, the Additional Lock-Up Agreement, and the Consideration Lock-Up Agreement, the "Lock-Up Agreements").

#### Nasdaq Compliance

On May 6, 2025, the Company received the May 2025 Nasdaq Letter. For discussion of the May 2025 Nasdaq Letter, please see Note 1 to Item 1 of this Report under the heading "Nasdaq Compliance".

#### Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

#### **Cautionary Notice Regarding Forward Looking Statements**

This Report contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as "anticipate," "believe," "estimate," "intend," "could," "should," "would," "may," "seek," "plan," "might," "will," "expect," "predict," "project," "forecast," "potential," "continue," negatives thereof or similar expressions. These forward-looking statements are found at various places throughout this Report and include information concerning possible or assumed future results of Datavault AI Inc,'s (the "Company", "our", "us" or "we") operations; business strategies; future cash flows; financing plans; plans and objectives of management; any other statements regarding future operations, future cash needs, business plans and future financial results, and any other statements that are not historical facts.

From time to time, forward-looking statements also are included in our other periodic reports on Form 10-K, 10-Q and 8-K, in our press releases, in our presentations, on our website and in other materials released to the public. Any or all of the forward-looking statements included in this Report and in any other reports or public statements made by us are not guarantees of future performance and may turn out to be inaccurate. These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors, including risks related to market, economic and other conditions; the Company's ability to continue as a going concern; the Company's ability to manage costs and execute on its operational and budget plans; and, the Company's ability to achieve its financial goals. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking statements. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Report. All subsequent written and oral forward-looking statements concerning other matters addressed in this Report and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Report.

Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.

#### Overview

Datavault AI is a pioneering technology licensing company that owns a portfolio of patented, secure platforms designed to redefine how data is managed, valued, and monetized in the modern era. Leveraging our proprietary HPC capabilities and advanced software, we aim to empower customers worldwide with revolutionary data solutions. At the heart of our offerings are our artificial intelligence (AI)-driven agents—branded as Data Vault®, DataValue®, DataScore®, and Data Vault Bank®. These tools harness generative AI to deliver enterprise-grade data management solutions tailored for the HPC landscape and the Web 3.0 paradigm. Our technology ensures data ownership immutability, experiential data observability, precise data asset valuation, and secure monetization—which we believe will unlock unprecedented opportunities for businesses in an increasingly data-driven world on which our executive leadership, with our engineering and software development teams, can capitalize. Datavault AI operates through two synergistic platforms (Data Science and Acoustic Science) to optimize our revenue generation.

The operating results presented in our historical financial statements represent the audio business and may not be indicative of our results following the asset purchase from EOS Technology Holdings Inc. We expect to derive a higher portion of revenues from the assets purchased from EOS Technology Holdings Inc. as compared to the revenue generated by the legacy Company. We have incurred, and expect to continue to incur, increased salaries and benefits expense due to hiring the additional employees it will take to monetize the economic benefit of the assets purchased in the Data Vault transaction. Other corporate costs are expected to increase such as legal and research and development expenses due to increased patent activity as well as sales and marketing expenses.

To date, our operations have been funded through sales of our common and preferred equity, proceeds from the exercise of warrants to purchase common stock, sale of debt instruments, and revenue from the sale of our products. Our condensed consolidated financial statements contemplate the continuation of our business as a going concern. However, we are subject to the risks and uncertainties associated with an emerging business, as noted above we have no established source of capital, and we have incurred recurring losses from operations since inception.

#### Comparison of the Three Months Ended March 31, 2025 and 2024

#### Revenue

Revenue for the three months ended March 31, 2025 was \$629,000 an increase of \$374,000 or 147%, compared to the revenue for the three months ended March 31, 2024 of \$255,000. The increase was a result of higher Consumer Audio Product sales and Component revenue which increased by \$333,000 and \$41,000, respectively compared to the three months ended March 31, 2024.

#### Gross Deficit and Operating Expenses

#### **Gross Profit (Deficit)**

Gross profit for the three months ended March 31, 2025 was \$69,000, an improvement of \$152,000, compared to gross deficit of \$83,000 for the three months ended March 31, 2024. The gross margin as a percent of sales was 11% for the three months ended March 31, 2025, compared to (33%) for the three months ended March 31, 2024. The improvement in gross deficit and gross margin as a percent of sales compared to the prior period is mainly attributable to the sale inventory with a lower cost basis.

#### Research and Development

Research and development expenses for the three months ended March 31, 2025 were \$2,361,000, an increase of \$646,000 compared to research and development expenses for the three months ended March 31, 2024 of \$1,715,000. The increase in research and development expenses is primarily related to an increase in headcount resulting in increased salaries and wages, benefits and stock-based compensation of \$356,000, legal expenses related to intellectual property of \$104,000 and consultants expense of \$25,000.

#### Sales and Marketing

Sales and marketing expenses for the three months ended March 31, 2025 were \$1,495,000, an increase of \$566,000, compared to the sales and marketing expenses for the three months ended March 31, 2024 of \$929,000. The increase in sales and marketing expenses is primarily related to an increase in headcount resulting in increased salaries and wages, benefits and stock-based compensation of \$178,000 and consulting expenses of \$311,000.

#### General and Administrative

General and administrative expenses for the three months ended March 31, 2025 was \$5,644,000, an increase of \$4,213,000, compared to the general and administrative expenses for the three months ended March 31, 2024 of \$1,431,000. The increase in general and administrative expenses is primarily related to increased amortization of intangibles of \$2,309,000 for the assets acquired from EOS Holdings that closed on December 31, 2024, an increase in headcount resulting in increased salaries and wages, benefits and stock-based compensation of \$533,000, increase in bonus of \$90,000, increased investor relations expense of \$669,000, increased consulting expense of \$421,000, and increased legal fees of \$211,000.

#### Interest Expense, net

Interest expense, net for the three months ended March 31, 2025 was \$120,000, a decrease of \$1,145,000, compared to the interest expense for the three months ended March 31, 2024 of \$1,265,000. The decrease, was primarily due to the Company's debt balance declining in the three months ended March 31, 2025.

#### Change in Fair Value of Warrant Liability

Change in fair value of warrant liability for the three months ended March 31, 2025 was \$17,000, compared to \$8,129,000 for the three months ended March 31, 2024. The change in fair value of warrant liability for the three months ended March 31, 2025 was due to our minimal number of warrants classified as liabilities outstanding. The change in fair value of the warrant liability for the three months ended March 31, 2024 was due to the issuance of warrants in January 2024 associated with our short term note and the issuance of warrants in connection with our February Public Offering and March 2024 Offering, offset partially by the subsequent decrease in the price of our common stock price at March 31, 2024 compared to the price of our stock on the date of the warrant issuance as well as the decline in our stock price from December 31, 2023, related to existing warrant liabilities.

#### **Liquidity and Capital Resources**

Cash and cash equivalents as of March 31, 2025 was \$171,000, compared to \$3,330,000, as of December 31, 2024.

We recorded net loss of \$9,563,000 for the three months ended March 31, 2025 and used net cash in operating activities of \$6,024,000. We incurred a net income of \$2,707,000 for the three months ended March 31, 2024 and used net cash in operating activities of \$3,540,000. The primary reasons for the increase in the use of net cash from operating activities during the three months ended March 31, 2025, was related to a net loss of \$9,563,000 offset by the non-cash add back of depreciation and amortization of \$2,321,000 in the three months ended March 31, 2025 compared to net income of \$2,707,000 in the prior year offset by net non-cash add backs of \$6,469,000.

We have financed our operations to date primarily through the issuance of equity securities, proceeds from the exercise of warrants to purchase common stock and sale of debt instruments. In February 2025, we received aggregate gross proceeds of approximately \$5.4 million in our registered direct offering. In January 2024, we received gross proceeds of \$600,000 from the issuance of promissory notes and common stock purchase warrants to certain accredited investors. In February 2024, we received gross proceeds of approximately \$10.0 million from the public offering of 1,025,600 units, with each unit consisting of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant, each to purchase one (1) share of common stock. In March 2024 we received gross proceeds of approximately \$2.3 million from the issuance of 417,833 shares of common stock, 93,342 pre-funded common stock warrants and the issuance of 511,175 warrants to purchase common stock.

#### **Off-Balance Sheet Arrangements**

We have no off-balance sheet arrangements.

#### Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting company, as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information required by this Item.

#### Item 4. Controls and Procedures.

#### **Evaluation of Disclosure Controls and Procedures**

We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission (the "SEC") rules and forms and to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer as appropriate, to allow timely decisions regarding required disclosure. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of our disclosure controls and procedures. Based on the foregoing evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2025, our disclosure controls and procedures was effective to provide reasonable assurance that the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms, and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our management, including our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), does not expect that our disclosure controls and procedures will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

#### **Changes in Internal Controls**

There were no changes in the Company's internal control over financial reporting that occurred during the three months ended March 31, 2025 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

#### PART II. OTHER INFORMATION

#### Item 1. Legal Proceedings

From time to time we may be involved in various claims and legal actions arising in the ordinary course of our business. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, or any of our subsidiaries in which an adverse decision could have a material adverse effect upon our business, operating results, or financial condition.

#### Item 1A. Risk Factors

As a smaller reporting company, the Company is not required to include the disclosure required under this Item 1A.

#### Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Information required by Item 701 of Regulation S-K as to all unregistered sales of equity securities of the Company during the period covered by this Report have previously been included in Current Reports on Form 8-K filed with the SEC.

### Item 3. Defaults Upon Senior Securities

None.

**Item 4. Mine Safety Disclosures** 

Not applicable.

**Item 5. Other Information** 

None.

## Item 6. Exhibits

Exhibit Number	Description
3.1(i)	Certificate of Amendment to WiSA Technologies, Inc.'s Certificate of Incorporation, filed with the Secretary of State of the State of
	Delaware on February 13, 2025 (incorporated by reference to the Company's Current Report on Form 8-K filed with the SEC on February
	<u>14, 2025).</u>
3.1(ii)	Bylaws of Summit Semiconductor, Inc. (incorporated by reference to the Company's Registration Statement on Form S-1/A (File No. 333-
	224267) filed with the SEC on July 2, 2018).
4.1	Form of Common Stock Purchase Warrant (incorporated by reference to the Company's Current Report on Form 8-K filed with the SEC on
4.2	February 14, 2025). Form of Placement Agent Warrant (incorporated by reference to the Company's Current Report on Form 8-K filed with the SEC on
	February 14, 2025).
4.3	Form of Convertible Promissory Note, dated March 16, 2025, by NYIAX, Inc. (incorporated by reference to the Company's Current Report
	on Form 8-K filed with the SEC on March 17, 2025).
4.4	Form of Senior Secured Promissory, Note, dated March 31, 2025, by certain investors (incorporated by reference to the Company's Current
	Report on Form 8-K filed with the SEC on March 31, 2025).
4.5	Form of Common Stock Purchase Warrant (incorporated by reference to the Company's Current Report on Form 8-K filed with the SEC on
	March 31, 2025).
10.1	Form of Securities Purchase Agreement, by and among the Company and certain investors, dated February 13, 2025 (incorporated by
10.2	reference to the Company's Current Report on Form 8-K filed with the SEC on February 13, 2025).
	Placement Agency Agreement, by and among the Company and Maxim Group LLC, dated February 13, 2025 (incorporated by reference to
10.3	the Company's Current Report on Form 8-K filed with the SEC on February 13, 2025).
	Form of Second Amendment to Asset Purchase Agreement, dated February 25, 2025, by and between the Company and CompuSystems, Inc. (incorporated by reference to the Company's Current Report on Form 8-K filed with the SEC on February 28, 2025).
10.4	Share Exchange Agreement, dated March 16, 2025, by and between the Company and NYIAX, Inc. (incorporated by reference to the
10.4	Company's Current Report on Form 8-K filed with the SEC on March 17, 2025).
10.5	Form of Securities Purchase Agreement, by and among the Company and certain investors, dated March 31, 2025 (incorporated by
	reference to the Company's Current Report on Form 8-K filed with the SEC on March 31, 2025).
10.6	Placement Agency Agreement, by and among the Company and Maxim Group LLC, dated March 31, 2025 (incorporated by reference to
	the Company's Current Report on Form 8-K filed with the SEC on March 31, 2025).
10.7	Form of Security Agreement (incorporated by reference to the Company's Current Report on Form 8-K filed with the SEC on March 31,
	<u>2025).</u>
10.8	Form of Subsidiary Guarantee (incorporated by reference to the Company's Current Report on Form 8-K filed with the SEC on March 31,
10.0	2025).  From a SThird Assess described Asset Districts Assessment of the March 21, 2025, he and between the Commence and C
10.9	Form of Third Amendment to Asset Purchase Agreement, dated March 31, 2025, by and between the Company and CompuSystems, Inc. (incorporated by reference to the Company's Current Report on Form 8-K filed with the SEC on April 2, 2025).
31.1	Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
31.2	Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
32.1	Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley
	Act of 2002 (furnished herewith).
32.2	Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley
	Act of 2002 (furnished herewith).
101	Interactive Data Files (embedded within the Inline XBRL document)

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

#### Datavault AI Inc.

Date: May 14, 2025 By: /s/ Nathaniel Bradley

Name: Nathaniel Bradley Title: Chief Executive Officer (Principal Executive Officer)

Date: May 14, 2025 By: /s/ Brett Moyer

Name: Brett Moyer Title: Chief Financial Officer (Principal Financial Officer)

# CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

- I, Nathaniel Bradley, certify that:
- 1. I have reviewed this Quarterly Report on Form 10-Q of Datavault AI Inc. (the "registrant"):
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a13a-15(f) and 15d-15(f)) for the registrant and have:
- a) Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
- b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
- c) Evaluated the effectiveness of the registrant's disclosure controls and procedures; and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
- d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 14, 2025 /s/ Nathaniel Bradley

Name: Nathaniel Bradley
Title: Chief Executive Officer
(Principal Executive Officer)

# CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

- I, Brett Moyer, certify that:
- 1. I have reviewed this Quarterly Report on Form 10-Q of Datavault AI Inc. (the "registrant"):
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a13a-15(f) and 15d-15(f)) for the registrant and have:
- a) Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
- b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
- c) Evaluated the effectiveness of the registrant's disclosure controls and procedures; and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
- d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 14, 2025 /s/ Brett Moyer

Name: Brett Moyer

Title: Chief Financial Officer
(Principal Financial Officer)

# CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Datavault AI Inc. (the "Company") for the period ended March 31, 2025 (the "Report"), I, Nathaniel Bradley, Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that:

- 1. The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and
- 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 14, 2025 /s/ Nathaniel Bradley

Name: Nathaniel Bradley
Title: Chief Executive Officer
(Principal Executive Officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

# CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Datavault AI Inc. (the "Company") for the period ended March 31, 2025 (the "Report"), I, Brett Moyer, Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that:

- 1. The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and
- 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 14, 2025 /s/ Brett Moyer

Name: Brett Moyer

Title: Chief Financial Officer (Principal Financial Officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.